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[57] ABSTRACT
Disclosed are methods for use in transferring nucleic acids
into central nervous system cells in vivo and in vitro and/or
for stimulating central nervous system cells. Neurotrophic
genes are shown to stimulate neurofilament cells and to
promote nerve cell growth, repair and regeneration in vivo.
Genetransfer protocols are disclosed for use in transferring
various nucleic acid materials into central nervous system
cells, as may be used in treating various pathologies of the
brain and spinal cord.
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CENTRAL NERVOUS SYSTEM CELLS
BACKGROUND OF THE INVENTION
The United States government has certain rights in the
present invention pursuant to Grants P01 NS3199801 and
NS21458 from the National Institutes of Health.
BACKGROUND OF THE INVENTION
A. Field of the Invention
The present invention relates generally to the field of
molecular biology. More particularly, certain embodiments
concern the transfer of genetic material into central nervous
system cells. In certain examples, the invention concernsthe
use of liposome-mediated delivery of nucleic acids encoding
neurotrophic factors to stimulate nervous system cell repair
and regeneration. Rescue of neurofilament protein following
traumatic brain injury (TBI) in vivo has been demonstrated.
B. Description of the Related Art
1. Neurotrophins Play Important Role in Cortical Injury
Recovery
Brief depolarization of primary septo-hippocampal cell
cultures can produce significant losses of neurofilament
proteins. Studies have indicated that brain-derived neu-
rotrophic factor (BDNF) increases neurofilaments in hip-
pocampal cell cultures (Yip et al., 1993) and increases
survival of cortical neurons (Ghoshet al., 1994).
Several articles have reported attempted treatments for
treating traumatic brain injury. Exogenous supplementation
of NGFhas been reported to spare neurons from death and
degeneration following injury (Hafti, 1986; Kromer, 1987;
Montero and Hafti, 1988; Williams et al., 1986) and to
increase choline acetyl transferase (CHAT)activity (Rylett
et al., 1993; Williams and Rylett, 1990).
NGFprevents degeneration of septal cholinergic neurons
following fimbria lesions or transfection (see e.g., Morseet
al., 1993). NGF and BDNF increase survival of septal
cholinergic neurons in vitro (see e.g., Alderson et al., 1990)
and increase choline acetyl transferase (ChAT) activity both
in vitro (see e.g., Alderson et al., 1990) and in intact animals
(see e.g., Rylett et al., 1993).
Observations indicate that TBI can result in disturbances
of cholinergic neurotransmission associated with impaired
release of acetylcholine in the hippocampus (Dixon etal.,
1993). In somecases, this disruption may cause nerve death,
which may ultimately lead to brain dysfunction. However,
the mechanism of cholinergic disturbance is not well-
understood, and therapies addressing this abnormality in
vivo have not been reported.
2. NGF and BDNF Expression in the Hippocampus
NGF and BDNF are members of the neurotrophin gene
family, as are neurotrophin-3, and neurotrophins-4/5 (NT-3,
NT-4/5). All are expressed in brain (for review, see Lindsay,
1993). During developmentin the adult rat brain BDNF and
NGF mRNAare particularly abundant in the hippocampus
(Maisonpierre et al., 1990b; Ernfors et al., 1990), a region
whichis preferentially vulnerable to TBI (Hayesetal., 1992;
Olenik et al., 1988).
3. BDNF and NGF Blunt Free Radical Damage
Formation of free radicals and subsequent lipid peroxi-
dation may contribute to TBI (Chan, 1992; Hall et al., 1992).
Giving NGFto adult rats protects their sympathetic ganglia
from 6-hydroxydopamine toxicity, a free radical generator
(Johnnson, 1980). Furthermore, in adult rats, long-term NGF
administration increases the activity of antioxidant enzymes














cultures of PC-12 cells is associated with specific increases
in catalase activity and glutathione levels due to stimulation
of glutathione redox reactions and synthesis (see e.g., Sam-
path et al., 1993).
4. BDNF and NGFInitiate Cytoskeleton Repair
NGF has been shown to initiate and maintain neurite
outgrowth in rat pheochromocytoma (PC12) cells (Greene
and Tischler, 1982), and is associated with increased levels
of B-tubulin (see e.g., Teng and Greene, 1993). BDNFhas
been shownto increase in vitro levels of neurofilament in
hippocampalcell cultures (Yip et al., 1993). However, the
role of these two growth factors in cytoskeletal stabilization
in vivo had not been determined.
5. BDNF and NGF Are Involved in Neurodegenerative
Disease
TBIis a risk factor for Alzheimer’s disease (Mortimeret
al., 1991), and in somecases, is also associated with diffuse
deposition of B/A, protein (Robertset al., 1991; Clintonet
al., 1991), the amyloidogenic protein of Alzheimer’s dis-
ease. Furthermore, in Alzheimer’s disease in situ hybridiza-
tion reveals significant decreases in BDNF mRNA(Phillips
et al. 1991). In aged rats, NGF increases high affinity
choline transport (Williams et al., 1990), stimulates Ach
release (Rylett et al., 1993) and also improves the perfor-
mance of age-impairedrats in spatial memory tasks (Fischer
et al., 1987).
6. BDNF and NGF Expression After CNS Injury is Only
Transient
Although various injuries to the CNS up-regulate the
production of neurotrophins and increase BDNF and NGF
mRNA in the hippocampus (Yang et al., 1993), in most
injuries, production of neurotrophins is not sustained long
enough to promote recovery. In TBI, prominent
up-regulation of BDNF mRNAoccurs in the hippocampus,
but only transiently, from 1 h to 6 h after injury (Yanget al.,
1993), and therefore levels of neurotrophins are not present
in substantial levels to effect cytoskeletal (e.g.,
neurofilament) rescue.
7. Providing Neurotrophins to CNS Cells is Desirable Fol-
lowing TBI
Many different approaches have been contemplated to
deliver exogenous neurotrophins to the nervous system of
mammals (Hafti, 1986; Kromer, 1987; Montero and Hafti,
1988; Williamset al., 1986), although significant limitations
imposed by protein degradation and by the blood-brain
barrier have restricted the clinical utility of these approaches
(Barinega, 1994).
Unfortunately, even though exogenous growth factors can
be delivered within the brain by means of mini-osmotic
pumpsthat release small amounts of neurotrophin into the
ventricular cavity or directly into the parenchyma (Hafti,
1986; Williams et al., 1986; Kromer, 1987; Montero and
Hafti, 1988), pumps must be mechanically regulated, and
often can fail. This method is particularly expensive and
inconvenient, since the stored growth factors in the pump
reservoir diminish in activity over time, and fresh amounts
of the neurotrophin must be constantly added.
Many drawbacks are also associated with these types of
treatment protocols, not the least of which is the expensive
and time-consuming purification of the recombinant pro-
teins from their host cells (Rylett et al., 1993; Morseetal.,
1993). Also, polypeptides, once administered to an animal
are more unstable than is generally desired for a therapeutic
agent, and they are susceptible to proteolytic attack.
Furthermore, the administration of recombinantproteins can




8. Focal Delivery of Neurotrophins
Investigators studying central nervous system injury have
long recognized that changes in specific proteins may be
important determinants of pathological responses to injury
and recovery of function of the injured brain. Gene transfer
has emerged as a potential way to introduce neurotrophins
into CNScells and tissues (Friedmann and Ginnah, 1993).
Methods currently used to introduce genes into localized
regions of the nervous system through stereotactic injection
include retroviral vectors, herpes virus vectors, adenoviral
vectors and grafted cells. Grafted cells have been most
extensively examined for growth factor production.
Studies grafting cells in brain capable of producing
growth factors have employed mouse sarcomacells, male
mouse submaxillary gland cells (Levi-Montalcini and
Cohen, 1960; Caramia et al., 1962) and sciatic nerve cells
(Richardson and Ebendal, 1982) or alternatively, in cell
culture followed by implantation within the brain (Gage et
al., 1987). Despite limited success with several different cell
types, including primary fibroblasts (Kawaja et al., 1992),
astrocytes and immortalized cell lines (Rosenberg et al.,
1988; Wolf et al., 1988) grafts remain only a temporary
solution, since most will eventually be rejected.
Although retroviral vectors are considered the most effi-
cient vectors for stable gene transfer into mitotic mammalian
cells and have been widely used in CNS cancer gene therapy
(Yamada etal., 1992; Ram et al., 1993; Culveret al., 1992),
they are unsuitable for post-mitotic CNScells, since with the
exception of some lentiviruses, retroviruses can integrate
only into chromosomesofdividing cells. Anothersignificant
limitation of retroviral vectors is their maximum insert
capacity of 5-7 kb (Gelinas and Teman, 1986).
Two methods using viral vectors have been described: 1)
Herpes Simplex virus, and 2) adenovirus-mediated delivery
systems. Unfortunately, however, neither are suitable for
treatment of TBI. Although Herpes virus is able to infect
post-mitotic cells and can be taken up anywhere along the
cell surface (Breakefield and DeLuca, 1991; Lycke et al.,
1988), its toxicity to nervous cells (Johnsonet al., 1992) and
its disruption of normal neuronal architecture (Huang etal.,
1992) make it unsuitable for treatment of TBI and CNScells.
Replication-deficient adenoviral vectors have also been
used to infect rat CNS cells in vitro and in vivo, since these
DNAviruses are able to infect post-mitotic cells (le Gal La
Salle et al., 1993), but unfortunately, they do not integrate
efficiently into the nuclear DNAofthe recipient cells, gene
expression occurs only transiently, often in an unpredictable
manner (Graham and Prevec, 1991; Horwitz, 1990). Further
limiting these methods in the treatment of TBI is their
limited transfection into neural cells, and the pathogenicity
and limited duration of gene expression of these vectors.
Several groups have investigated the possibility of using
liposomes as a means of mediating delivery of genetic
information into nervous system cells in vitro, but unfortu-
nately these methods were disappointing. For example,
using the EF. coli B-Gal reporter gene in liposome-mediated
transfection of low density cultures of rat hippocampal
neurons, the transfection efficiency was less than 1% of the
whole cell population, and the small fraction of transfected
cells was mostly neuronal (Drazba and Ralston, 1993).
Likewise, an ex vivo method employing cationic lipo-
somesto transfect primary rodent neuronalcell cultures with
a gene encoding B-Gal (Ono et al., 1990) showed only
limited success, when the cell types which incorporated and
expressed the injected cDNA were not delineated.
9. Deficiencies in the Prior Art
A methodoftreating a variety of central nervous system














toxic proteins would have important therapeutic potential.
Increasing expression of trophic factors which have been
shown to enhance recovery of function following trauma to
the brain and spinal cord would be particularly desirable.
More than 500,000 patients annually are hospitalized for
traumatic brain injury. More than 10,000 patients are treated
for spinal cord injury and 750,000 patients for stroke.
Neurodegenerative diseases, organically-based psychologi-
cal disorders and chronic pain are all widely recognized
major health problemsin the United States. The presence of
the blood-brain barrier significantly confoundsthe choice of
routes for administration of neurotrophins.
It is clear, therefore, that a new method capable of
promoting nervous system cell repair and regeneration in
vivo would represent a significant scientific and medical
advance with immediate benefits to a large number of
patients. A method readily adaptable for use with a variety
of growth factors and other genes would be particularly
advantageous. Rescue of neurofilament loss due to TBI by
increasing the availability of neurotrophins both ex vivo and
in vivo would represent a significant improvement in the
treatment of central nervous system injury.
SUMMARYOF THE INVENTION
The present invention overcomes one or more of these
and other drawbacks inherent in the prior art by providing
novel methods for use in transferring nucleic acids into
post-mitotic nervous system cells and tissues, and for pro-
moting nervous system cell repair and regeneration. Certain
embodiments of the invention rest, generally, with the
inventors’ surprising finding that nucleic acids can be effec-
tively transferred to post-mitotic cells by liposome-mediated
transfection protocols both in vivo and ex vivo. Moreover,
in certain embodiments, the transfer of a neurotrophic gene
stimulates nervous system cell repair in an animal.
The invention, in general terms, thus concerns methods
for transferring a nucleic acid segment into neural cells or
tissues. The methods of the invention generally comprise
contacting neural cells or tissues with a composition com-
prising a nucleic acid segment in a manner effective to
transfer the nucleic acid segmentinto the cells.
Alternatively, the neural cells may be located within a
central nervous system (CNS) tissue site of an animal, when
the nucleic acid composition would be applied to the site in
order to effect, or promote, nucleic acid transfer into CNS
cells in vivo. In transferring nucleic acids into CNS cells
within an animal, a preferred method involvesfirst adding
the genetic material to a liposome complex and then using
the liposome-DNA complex to transfect an appropriate
tissue site within the animal.
An extremely wide variety of genetic material can be
transferred to CNScells or tissues using the compositions
and methodsof the invention. For example, the nucleic acid
segment may be DNA(double or single-stranded) or RNA
(e.g., MRNA, tRNA, rRNA); it may also be a “coding
segment”, i.e., one that encodes a protein or polypeptide, or
it may be an antisense nucleic acid molecule, such as
antisense RNAthat may function to disrupt gene expression.
The nucleic acid segments may thus be genomic sequences,
including exons or introns alone or exons and introns, or
coding cDNAregions, or in fact any construct that one
desires to transfer to a CNScell ortissue.
Suitable nucleic acid segments may also be in virtually
any form, such as naked DNA or RNA,including linear
nucleic acid molecules and plasmids; functional inserts
within the genomes of various recombinantviruses, includ-
6,096,716
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ing viruses with DNA genomesand retroviruses; and any
form of nucleic acid segment, plasmid or virus associated
with a gold particle which may be employed in connection
with the gene gun technology.
The invention may be employed to promote expression of
a desired gene in CNS cells or tissues and to impart a
particular desired phenotype to the cells. This expression
could be increased expression of a gene that is normally
expressed (i.e., “over-expression”), or it could be used to
express a gene that is not normally associated with CNS
cells in their natural environment. Alternatively, the inven-
tion may be used to suppress the expression of a gene that
is naturally expressed in such cells and tissues, and again, to
change or alter the phenotype. Gene suppression may be a
way of expressing a gene that encodesa protein that exerts
a down-regulatory function, or it may utilize antisense
technology.
1. Central Nervous System Cells and Tissues
In certain embodiments, this invention provides advanta-
geous methods for using genes to stimulate CNScells. As
used herein, the term “CNScells”refers to any orall of those
cells that have the capacity to ultimately form, or contribute
to the formation of, central nervous system tissue. This
includes various cells in different stages of differentiation,
such as, for example, developmentally different fetal and
adult neural cells, as well as neurons, astroglia, microglia,
and oligodendrocytes, and the like. CNS cells also include
cells that have been isolated and manipulated in vitro,e.g.,
subjected to stimulation with agents such as cytokines or
growth factors or even genetically engineered cells. The
particular type or types of CNS cells that are stimulated
using the methods and compositions of the invention are not
important, so long as the cells are stimulated in such a way
that they are activated and, in the context of in vivo
embodiments, ultimately give rise to CNS cells andtissue.
CNS cells may also be isolated from animal or human
tissues and maintained in an in vitro environment.Isolated
cells may be stimulated using the methods and compositions
disclosed herein and, if desired, be returned to an appropri-
ate site in an animal where CNScell repair is to be
stimulated. In such cases, the nucleic-acid containing cells
would themselves be a form of therapeutic agent. Such ex
vivo protocols are well knownto those of skill in the art.
In important embodiments of the invention, the CNScells
and tissues will be those cells and tissues that may be
damaged and that one desires to treat. Accordingly, in
treatment embodiments,thereis no difficulty associated with
the identification of suitable target cells to which the present
therapeutic compositions should be applied. All that is
required in such cases is to obtain an appropriate stimulatory
composition, as disclosed herein, and contact the site of the
injury or defect with the composition. The nature of this
biological environmentis such that the appropriate cells will
become activated in the absence of any further targeting or
cellular identification by the practitioner.
Certain methods of the invention involve, generally, con-
tacting CNS cells with a composition comprising one or
more neurotrophic genes (with or without additional genes,
proteins or other biomolecules) so as to promote expression
of said gene in said cells. As outlined above, the cells may
be contacted in vitro or in vivo. This is achieved, in the most
direct manner, by simply obtaining a functional neurotrophic
gene construct and applying the construct to the cells. The
inventors surprisingly found that there are no particular
molecular biological modifications that need to be per-
formed in order to promote effective expression of the gene















containing a suitable DNA molecule, e.g., a linear DNA
molecule, or DNA in the form of a plasmid or other
recombinantvector, that contains the gene of interest under
the control of a promoter, along with the appropriate termi-
nation signals, is sufficient to result in uptake and expression
of the DNA, with no further steps being necessary.
2. Neurotrophic Genes
As used herein, the term “neurotrophic gene” is used to
refer to a gene or DNA codingregion that encodesa protein,
polypeptide or peptide that is capable of promoting, or
assisting in the promotion of, nerve cell formation, or one
that increases the rate of primary nerve cell growth or
healing (or even a gene that increases the rate of neurofila-
ment tissue growthor healing). The terms promoting, induc-
ing and stimulating are used interchangeably throughoutthis
text to refer to direct or indirect processes that ultimately
result in the formation of new CNStissue or in an increased
rate of CNS cell repair. Thus, a neurotrophic gene is a gene
that, when expressed, causes the phenotype of a cell to
changeso that the cell either differentiates, stimulates other
cells to differentiate, attracts CNS-forming cells, or other-
wise functions in a mannerthat ultimately gives rise to new
CNStissue.
A variety of neurotrophic genes are now known,all of
which are suitable for use in connection with the present
invention. Neurotrophic genes and the proteins that they
encode include, for example, BDNF, NGF,fibroblast growth
factor (FGF), insulin-like growth factor, glial cell line-
derived neurotrophic factor, ciliary neurotrophic factor,
endothelial growth factor (EGF); chemotactic or adhesive
peptides or polypeptides; morphogenetic proteins; and even
growth factor receptor genes. Any of the above or other
related genes, or DNA segments encoding the active por-
tions of such proteins, may be used in the novel methods of
the present invention.
As knownto those of skill in the art, the original source
of a recombinant gene or DNA segment to be used in a
therapeutic regimen need not be of the same species as the
animal to be treated. In this regard, it is contemplated that
any recombinant growth factor (GF) or neurotrophic gene
may be employed to promote CNScell repair or regenera-
tion in a human subject or an animal, such as, e.g., a horse.
Particularly preferred genes are those from human.
However, since the sequence homology for genes encoding
nerve growth factors is highly-conserved across species
lines, rodent and bovine species may also be contemplated
as sources, in that such genes and DNAsegmentsare readily
available, with the human or rodent formsof the gene being
most preferred for use in human treatment regimens.
Recombinantproteins and polypeptides encoded byisolated
DNA segments and genes are often referred to with the
prefix “r” for recombinant and “rh” for recombinant human.
As such, DNA segments encoding rGFs, such as rhaNGF or
rhBDNF,etc. are contemplated to be particularly useful in
connection with this invention. Any recombinant neu-
rotrophic gene would likewise be very useful with the
methods of the invention.
The definition of a “GF gene”, as used herein, is a gene
that hybridizes, underrelatively stringent hybridization con-
ditions (see, e.g., Maniatis et al., 1982), to DNA sequences
presently known to include GF gene sequences.
The definition of a “neurotrophic gene”, as used herein,is
a gene that hybridizes, underrelatively stringent hybridiza-
tion conditions (see, e.g., Maniatis et al., 1982, Molecular
Cloning: A Laboratory Manual, Cold Spring Harbor




To prepare a neurotrophic gene segment or cDNA one
may follow the teachings disclosed herein and also the
teachings of any of patents or scientific documents specifi-
cally referenced herein. One may obtain a hGF or neu-
rotrophic gene DNA segment using molecular biological
techniques, such as polymerase chain reaction (PCR™) or
screening a cDNA or genomic library, using primers or
probes with sequences based on the above nucleotide
sequence. The practice of such techniquesis a routine matter
for those of skill in the art, as taught in various scientific
articles, such as Sambrooket al. (1989), incorporated herein
by reference. Certain documents further particularly
describe suitable mammalian expression vectors, e.g., U.S.
Pat. No. 5,168,050, incorporated herein by reference. Neu-
rotrophic genes and DNA segments that are particularly
preferred for use in certain aspects of the present methods
are the NGF and BDNFgenes.
It is also contemplated that one may clone further genes
or cDNAs that encode a growth factor or neurotrophic
protein or polypeptide. The techniques for cloning DNA
molecules, 1.e., obtaining a specific coding sequence from a
DNAlibrary that is distinct from other portions of DNA,are
well knownin the art. This can be achieved by, for example,
screening an appropriate DNA library which relates to the
cloning of a CNS healing gene. The screening procedure
may be based on the hybridization of oligonucleotide
probes, designed from a consideration of portions of the
amino acid sequence of known DNA sequences encoding
related neurotrophic proteins. The operation of such screen-
ing protocols are well knownto those of skill in the art and
are described in detail in the scientific literature, for
example, in Sambrooket al. (1989), incorporated herein by
reference.
Techniques for introducing changes in nucleotide
sequencesthat are designedto alter the functional properties
of the encoded proteins or polypeptides are well known in
the art, e.g., U.S. Pat. No. 4,518,584, incorporated herein by
reference, which techniques are also described in further
detail herein. Such modifications include the deletion, inser-
tion or substitution of bases, and thus, changes in the amino
acid sequence. Changes may be made to increase the neu-
rotrophic activity of a protein, to increase its biological
stability or half-life, to change its glycosylation pattern, and
the like. All such modifications to the nucleotide sequences
are encompassed by this invention.
It will, of course, be understood that one or more than one
neurotrophic gene may be used in the methods and compo-
sitions of the invention. The nucleic acid delivery methods
may thus entail the administration of one, two, three, or
more, neurotrophic genes. The maximum numberof genes
that may be applied is limited only by practical
considerations, such as the effort involved in simultaneously
preparing a large number of gene constructs or even the
possibility of eliciting an adverse cytotoxic effect. The
particular combination of genes may be twoor moredistinct
GFgenes;or it may be such that a GF gene is combined with
another neurotrophic gene and/or another protein such as a
cytoskeletal protein, cofactor or other biomolecule; a hor-
mone or growth factor gene may even be combined with a
gene encoding a cell surface receptor capable of interacting
with the polypeptide product of the first gene.
In using multiple genes, they may be combined on a
single genetic construct under control of one or more
promoters, or they may be prepared as separate constructs of
the same or different types. Thus, an almost endless com-
bination of different genes and genetic constructs may be














or their use may otherwise result in, achieving synergistic
effects on cell stimulation and CNScell growth, any and all
such combinations are intended to fall within the scope of
the present invention. Indeed, many synergistic effects have
been described in the scientific literature, so that one of
ordinary skill in the art would readily be able to identify
likely synergistic gene combinations, or even gene-protein
combinations.
It will also be understood that, if desired, the nucleic
segment or gene could be administered in combination with
further agents, such as, e.g., proteins or polypeptides or
various pharmaceutically active agents. So long as a
liposomal-genetic material complex forms part of the
composition, there is virtually no limit to other components
which mayalso be included, given that the additional agents
do not cause a significant adverse effect upon contact with
the target cells or tissues. The nucleic acids may thus be
delivered along with various other agents as required in the
particular instance.
3. Gene Constructs and DNA Segments
As used herein, the terms “gene” and “DNAsegment”are
both used to refer to a DNA molecule that has been isolated
free of total genomic DNAofa particular species. Therefore,
a gene or DNA segmentencoding a neurotrophic generefers
to a DNA segment that contains sequences encoding a
neurotrophic protein, but is isolated away from,or purified
free from, total genomic DNAofthe species from which the
DNAisobtained. Included within the term “DNAsegment”,
are DNA segments and smaller fragments of such segments,
and also recombinant vectors, including, for example,
plasmids, cosmids, phage, retroviruses, adenoviruses, and
the like.
The term “gene” is used for simplicity to refer to a
functional protein or peptide encoding unit. As will be
understood by those in theart, this functional term includes
both genomic sequences and cDNA sequences. “Isolated
substantially away from other coding sequences” meansthat
the gene ofinterest, in this case, a neurotrophic gene, forms
the significant part of the coding region of the DNA
segment, and that the DNA segment does not contain large
portions of naturally-occurring coding DNA,such as large
chromosomal fragments or other functional genes or cDNA
coding regions. Of course, this refers to the DNAsegmentas
originally isolated, and does not exclude genes or coding
regions, such as sequences encoding leader peptides or
targeting sequences, later added to the segment by the hand
of man.
This invention provides novel ways in which to utilize
various known neurotrophic DNA segments and recombi-
nant vectors. As described above, many such vectors are
readily available, one particular detailed example of a suit-
able vector for expression in mammalian cells is that
described in U.S. Pat. No. 5,168,050, incorporated herein by
reference. However, there is no requirement that a highly
purified vector be used, so long as the coding segment
employed encodes a neurotrophic protein and does not
include any coding or regulatory sequences that would have
an adverse effect on CNS cells. Therefore, it will also be
understood that useful nucleic acid sequences may include
additional residues, such as additional non-coding sequences
flanking either of the 5' or 3' portions of the coding region
or may include various internal sequences, 1e., introns,
which are known to occur within genes.
After identifying an appropriate neurotrophic gene or
DNAmolecule, it may be inserted into any one of the many
vectors currently knownin the art, so that it will direct the
expression and production of the neurotrophic protein when
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incorporated into a CNScell. In a recombinant expression
vector, the coding portion of the DNA segmentis positioned
under the control of a promoter. The promoter may bein the
form of the promoter which is naturally associated with a
neurotrophic gene, as may be obtained by isolating the 5'
non-coding sequences located upstream of the coding seg-
ment or exon, for example, using recombinant cloning
and/or PCR™ technology, in connection with the composi-
tions disclosed herein.
In other embodiments, it is contemplated that certain
advantages will be gained by positioning the coding DNA
segment under the control of a recombinant, or
heterologous, promoter. As used herein, a recombinant or
heterologous promoter is intended to refer to a promoterthat
is not normally associated with a neurotrophic gene in its
natural environment. Such promoters may include those
normally associated with other neurotrophic genes, and/or
promoters isolated from any other bacterial, viral,
eukaryotic, or mammalian cell. Naturally, it will be impor-
tant to employ a promoterthat effectively directs the expres-
sion of the DNA segment in CNScells.
The use of recombinant promoters to achieve protein
expression is generally knownto those of skill in the art of
molecular biology, for example, see Sambrooket al. (1989).
The promoters employed may be constitutive, or inducible,
and can be used under the appropriate conditions to direct
high level or regulated expression of the introduced DNA
segment. The currently preferred promoters are those such
as CMV, RSV LTR, the SV40 promoter alone, and the SV40
promoter in combination with the SV40 enhancer.
4. Liposome-Mediated Transfection
The therapeutic potential for liposome-mediated gene
transfer in the injured CNS has been successfully demon-
strated using the rodent model. Based on existing evidence
which showsthat the systemic injection of cDNA:cationic
liposome complexes into animals is non-toxic (Stewart et
al., 1992), the inventors have developed liposome-mediated
gene transfer methods which demonstrate the surprising
rescue of NF loss following TBI. These methods have
proven to be superior to those methodsofthe prior art in the
transfection of post-mitotic cells. Moreover, the present
invention has demonstrated that liposome-mediated gene
transfer can be used to effectively incorporate large gene
inserts. Specific tissues and cell types may be targeted in
vivo by the use of selected promoter-enhancer elements that
are tissue and cell type specific, administration of the
plasmid regionally into selected tissue compartments (Holt
et al., 1990) and coupling atargeting ligand to the liposomal
surface (Debset al., 1987).
The present invention provides for a liposomal-mediated
system for transfecting cDNA of neurotrophins into central
nervous system cells, and represents the first successful use
of cationic liposomes as efficient and clinically relevant
vectors for the transfer of genes into cells of the central
nervous system. Efficient transfection of genes mayresult in
therapeutic levels of expression of neurotrophins and other
proteins which could be useful in the treatment of a variety
of central nervous system pathologies including mechanical
injury to the brain and spinal cord, stroke, neurodegenerative
diseases (e.g., Alzheimer’s disease, Parkinson’s disease),
organically-mediated psychological disorders (e.g.,
depression, panic disorders) and chronic pain syndromes.
5. Methods of DNA Transfection
Technology for introduction of DNA into cells is well-
knownto those of skill in the art. Four general methods for
delivering a gene into cells have been described: (1) chemi-














methods such as microinjection (Capecchi, 1980), elec-
troporation (Wong and Neumann,1982; Fromm et al., 1985)
and the gene gun (Yang et al., 1990); (3) viral vectors
(Clapp, 1993; Danos and Heard, 1992; Eglitis and Anderson,
1988); and (4) receptor-mediated mechanisms (Wuetal.,
1991; Curiel et al., 1991; Wagner et al., 1992).
Chemical and physical methods of DNAtransfer are
relatively inefficient processes and are not applicable to
studies in which gene transfer needs to occurin relatively
high percentage of cells. Therefore, much effort has focused
on developing viral vectors for gene transfer and on devel-
oping new compounds, such as liposomes, that would allow
DNAtransfer at relatively high efficiency. Importantclinical
disadvantages of viral vectors include the possibility of
replication-competent virus production, immunological
reactions and toxicity.
Liposomes have also been used successfully with a num-
berof cell types that are normally resistant to transfection by
other procedures including T cell suspensions, primary
hepatocyte cultures and PC 12 cells (Chang and Brenner,
1988; Muller et al., 1990). In addition, liposomesare free of
the DNA length constraints that are typical of viral-based
delivery systems. Liposomes have been usedeffectively to
introduce genes, drugs (Heath et al., 1986; Storm et al.,
1988; Balazsovits et al., 1989), radiotherapeutic agents
(Pikul et al., 1987), enzymes (Imaizumiet al., 1990; Imai-
zumi et al., 1990), viruses (Faller and Baltimore, 1984;
Wilsonet al., 1977; Wilson et al., 1979),transcription factors
(Debset al., 1990) and allosteric effectors (Nicolau et al.,
1979) into a variety of cultured cell lines and animals. In
addition, several successful clinical trails examining the
effectiveness of liposome-mediated drug delivery have been
completed (Lopez-Berestein et al., 1985; Coune, 1988).
Furthermore, several studies suggest that the use of lipo-
somesis not associated with autoimmuneresponses,toxicity
or gonadal localization after systemic delivery (Nabelet al.,
1992; Mori and Fukatsu, 1992).
Introduction of the liposome-cDNAtransfection complex
may be by injection, and may be systemic injections into
peripheral arteries or veins, including the carotid or jugular
vessels. Injection may also be directly into the central
nervous system, either by intraventricular administration, or
directly into the brain tissue itself. Such injection may be
facilitated by the use of mini-osmotic pumps for long-
duration infusion, or an intraparenchymal injection appara-
tus with ventricular cannuli or other intraparenchymal
devices. In other embodiments, it may be desirable to
introduce the liposome-cDNA complex directly into the
spinal cord or surrounding epidural space. This is particu-
larly important in the instance of spinal cord injury. In such
cases, either direct injections into the spinal cord
(intramedullary) or into the subarachnoid space would be
desirable. In other cases, direct or indirect puncture of the
epidural space may be desired. In the case of brain injury, or
in circumstances where introduction of GFs into the brain is
desirable, such injection may be madeinto the ventricle, the
hippocampus, the cortex, or directly into the spinal cord.
6. Neurofilaments
Previous histopathologic examination of severe human
TBI (Adamset al., 1983; Gennarelli et al., 1989) and animal
cortical impact models (Dixonet al., 1991) have pointed to
the prevalence of axonal damage as a feature of injury
pathology. Diffuse axonal injury (DAD) is found in injured
cortex and is characterized by the histopathologic observa-
tion of retraction bulbs caused by mechanical forces radi-
ating from the cortical impact site. Retraction bulbs are
characteristic of post-injury cortex but are rarely observed in
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injured hippocampi (Adamset al., 1983; Dautingy et al.,
1988; Finemanet al., 1993; Troost et al., 1992). A similar
distribution of NF protein changes has been observed in the
present invention. Loss of NF68 and NF200 was found in
cortical tissue (no hippocampal loss) and was predominant
in the ipsilateral hemisphere. Thus, the regional distribution
of TBI-induced NF protein loss was similar to that previ-
ously reported for axonal damage following TBI in human
and animal cortical impact models (Adamset al., 1983;
Dixon et al., 1991; Gennarelli et al., 1989; Yaghmai and
Povlishock, 1992). In contrast to earlier qualitative work,
these studies indicate that the overall effect of TBI on NF68
protein levels throughout the cortex is reduction, although
site-specific increases of NF68 in retraction bulbs have been
documented (Yaghmai and Povlishock, 1992).
The present invention departs from previous qualitative
studies and demonstrates the effects of severe TBI on the
levels of cytoskeletal proteins, which are primary compo-
nents of axons and dendrites. The axonal damage observed
following severe TBI is likely to be associated with an
extensive and persistent loss of key neurofilament proteins.
Further, the presence of lw-MW NF68breakdown products
implicates TBI-induced proteolysisin the loss of NF protein.
A surprising aspect of the present invention is the pres-
ence of low MW immunopositive bands in injured samples
associated with loss of the parent NF68 protein. These bands
do not occur substantially in naive or sham-injured samples
but appear prominently in 3 h, 1 day, and 7 days post-injury
samples. These bands may represent NF68 breakdownprod-
ucts (BDPs) produced by the action of proteases on the
parent NF68protein, since prominent BDPs at MWsof 56
kDa and 52 kDa were observed in Western analyses.
Interestingly, the action of the calcium-activated protease,
calpain, on neurofilament protein produces immunopositive
cleavage products of 57 kDa and 53 kDa. These NF68 BDPs
have been observed in both in vivo and in vitro studies
(Kamakura et al., 1985; Schlaepfer et al., 1984; Schlaepfer
and Zimmerman, 1985a, 1985b). The fragments correspond
to the amino terminal, alpha-helical domain commontoall
neurofilament proteins (NF68, NF150, NF200). Therefore,
NF68 BDPsidentified here may be fragments produced by
cleavage of NF68, NF150, and/or NF200 (Schlaepferet al.,
1984; Schlaepfer and Zimmerman, 1985a, 1985b). Since the
existing anti-NF200 monoclonal antibodies target the car-
boxyl terminal domain present in NF200 (and consequently
do not recognize the low molecular weight BDPs containing
the alpha-helical domain), other antibodies are required to
determine the relative contribution of NF68, NF150, or
NF200 to the low MW BDPs.
Although other proteases also produce immunopositive
fragments, such as cathepsins B and D, trypsin, and
alphachymotrypsin, the MWsof the proteolytic fragments
were substantially lower and did not resemble the pattern
observed in post-TBI (Chin et al., 1983; Kamakuraetal.,
1985; Nixon and Marotta, 1984). The BDPs observedin this
study match very closely those produced by calpain-
dependent proteolysis and suggest that calpain activation
contributes to the loss of neurofilament protein observed
post-injury. These breakdown products are of particular
interest because they are believed to be involved in the
maintenance of neurofilament metabolism (Schlaepferetal.,
1984; Schlaepfer and Zimmerman, 1985a, 1985b). Thus, the
action of TBI may produce alterations of neurofilament
function by two mechanisms: (1) by reduction of NF68 and
NF200 protein levels and (2) by production of metabolically
significant breakdown products.
Like other neuropathologic conditions, such as ischemia














in part, by prolonged excitotoxicity and subsequent calcium
influx, leading to a lossof intracellular calctum homeostasis.
Under more severe TBI magnitudes, such as those experi-
enced in cortical impact models, excitotoxic injury is
accompanied by the presence of mechanical damage.
Mechanical forces caused by injury can disrupt membrane
integrity and, thereby, further contribute to intracellular
calcium levels. The cascade of biochemical pathologic con-
ditions that may occur under conditions of high intracellular
calcium would include activation of calciumdependent pro-
teases (Siman and Noszek, 1988). Significantly, lateral fluid
percussion injury (a model of TBI that produces severe
injury) causes higher levels of intracellular calcium in
injured cortex than in the corresponding hippocampi
(Fineman et al., 1993). These findings may explain the
distribution of calpain-like BDPsin the cortex, where injury
and calcium accumulation may be most severe, and its
notable absence in the hippocampus.
An important aspect of the present invention is the use of
two models of TBI which reproduce features of moderate
diffuse TBI or more severe injury with focal tissue damage.
This approach permits the study of liposome-mediated gene
transfection across a clinically-relevant range of injury lev-
els. Fluid percussion injury, a model of diffuse TBI, pro-
duces deficits in motor function and spatial memoryperfor-
mancein part by producing sublethal excitotoxic damage of
neurons (Hayeset al., 1992). The hippocampusis preferen-
tially vulnerable in this model (Lyeth et al., 1990). Several
studies have documented that fluid percussion TBI does not
produce cerebral ischemia (DeWitt et al., 1989), but sus-
tained blood-brain barrier opening is observed (Jiang etal.,
1992). Cortical impact, a model of severe TBI, produces
focal contusions and more DAI than fluid percussion injury
(Dixonet al., 1991). Excitotoxic injury processes also con-
tribute to enduring behavioral deficits following cortical
impact (Palmeret al., 1993).
Aparticular aspect of the present invention is the evidence
provided which suggests NF proteolysis plays an important
role in pre-necrotic axonal changes after TBI. The loss of
NF68 and NF200 proteins, as well as the appearance of
NF68 BDPs,strongly suggests the occurrence of pathologic
proteolysis post-injury. Data describing NF protein loss
secondary to calpain activation in models of spinal cord
injury further support the protease hypothesis (Banik etal.,
1992; Schlaepfer and Zimmerman, 1985a). Importantly, the
observation of immunopositive NF68 BDPsin the cortical
impact model complicates the interpretation of immunohis-
tochemical data and could provide an alternate explanation
for localized increases in NF68 immunoreactivity post-
injury (Povlishock, 1993; Yaghmai and Povlishock, 1992).
Increased NF68 antigenicity in immunohistochemical stud-
ies may represent BDPs of NF68, as well as NF150 and
NEF200.
In laboratory models of ischemia, NF protein loss has
been demonstrated after focal ischemic damage (Inuzuka et
al., 1990b), as well as after global ischemia in both rats
(Kaku et al., 1993) and gerbils (Kamakura et al., 1985;
Nakamura et al., 1992). Similarly, cytoskeletal damage
caused by ischemia has been prevented by administration of
antiproteolytic compounds (Araiet al., 1990, 1991; Inuzuka
et al., 1990a; Lee et al., 1991).
Tworelated hypotheses have been proposed that address
the mechanism of axonal damage and diffuse axonal injury
following TBI (Balentine, 1985; Povlishock, 1993). Thefirst
postulate implicates primary disruption of NF, possibly
associated with altered NF phosphorylation, as contributing
to NF disassembly and localized increases in NF antigenic-
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ity found in retraction balls (Povlishock, 1993; Yaghmai and
Povlishock, 1992). To date, no direct evidence exists for
altered phosphorylation of NF after TBI. The second
premise suggests that TBI activates calciumdependent pro-
teases that cause subsequent NF disruption and proteolysis.
7. Traumatic Brain Injury
Axonal injury has long been thought to be a primary
pathologic feature of traumatic brain injury (TBI). Animal
models of severe TBI and human post-injury pathology
demonstrate axonal damage (Gennarelli et al., Yaghmai and
Povlishock, 1992). A central polemic in TBI investigation is
the relative roles of structural determinants vs. concurrent
biochemical derangements as the crucial pathologic events
post-injury. In human studies, investigators have identified
diffuse axonal injury (DAI) as the key pathologic feature
responsible for the neurobehavioral deficits that accompany
human TBI (Adamset al., 1983; Gennarelli et al., 1989).
Current studies investigating DAI after TBI have been
predominantly pathomorphologic and qualitative in nature.
Recent investigations of the role of NF68 in DAI pathology
are a noteworthy exception (Yaghmai and Povlishock,
1992). Although axonal dysfunction may play an important
role in TBI pathology, no causal relationship has been
established between DAI and post-injury neurobehavioral
deficits. In fact, numerousstudies have revealed that func-
tionally normal neurotransmission can be preserved in path-
waysthat have suffered significant loss of fibers (Beattie et
al., 1988; Sautter et al., 1991). Thus, a comprehensive
quantitative assessment of cytoskeletal alterations would
contribute to the understanding of DAI andits role in TBI
pathology.
Rodent models of TBI cause neurobehavioral deficits,
including motor and memory disturbances, that resemble
those seen in human patients (Hamm et al., 1992; Lyeth et
al., 1990). Little is known of the molecular events leading to
post-injury pathology in these animal models. Recent labo-
ratory studies have determined that TBI inducesa significant
decrease in the protein levels of key dendritic cytoskeletal
elements (Taft et al., 1992, 1993), including microtubule-
associated protein 2 (MAP2). Post-TBI excitotoxicity
(Gorman et al., 1989; Hayes et al., 1992), loss of calcium
homeostasis (Finemanetal., 1993) and pathologic activation
of calcium-dependent proteases (Taft et al., 1992, 1993)
(e.g., calpain) may be principal causes of cytoskeletal deg-
radation. Although calpains are found in both axonal and
dendritic environments (Perlmutter et al., 1988), previous
examination of cytoskeletal pathology after TBI has focused
on dendritic cytoskeletal elements (MAP2)(Taftet al., 1992,
1993). Neurofilament proteins (Kamakura et al., 1985;
Schlaepferet al., 1984; Schlaepfer and Zimmerman, 1985b),
MAP2 (Johnsonet al., 1991), spectrin (Simanet al., 1984),
and other cytoskeletal proteins are substrates for calpain-
dependent proteolysis.
Therapeutically relevant strategies for manipulating pro-
duction of these proteins may ultimately have important
implications for the treatment of TBI. TBIis associated with
disturbances of the blood-brain barrier which may enhance
delivery of transgenes by vectors that would otherwise have
restricted access to the CNS. In contrast to neurodegenera-
tive diseases, experimental TBI can producerelatively rapid
changes in specific proteins, facilitating assessments of the
effects of gene therapy on post-traumatic gene expression.
8. Neuronal Architecture
Neurofilament (NF) proteins are primary components of
the neuronal cytoarchitecture, including axons and dendrites
(Shaw, 1986). NFs consist of three separate protein elements














(Hoffman and Lasek, 1975). These subunits have apparent
molecular weights of 200 kDa (NF-H), 150 kDa (NF-M),
and 68 kDa (NF-L) as estimated by gel electrophoresis
(Dautingy et al., 1988). The 68-kDa subunit is an assembly
protein found predominantly in the neurofilament core, and
the 150-kDa and 200-kDa subunits are cross-linking pro-
teins found in the connecting branches.
All NF triplet proteins exhibit significant sequence
homology in the amino terminal, alpha helical domain. The
150-kDa and 200-kDa subunits possess highly repeating
lysine-serine-proline (KSP) sequences, which are heavily
phosphorylated and contribute to anomalous electrophoretic
mobilities (Julien and Mushynski, 1982; Nixon and Sihang,
1991).
Neurofilament rescue refers to the prevention of neu-
rofilament deterioration, and/or to the maintenance and/or
promotion of neurofilament restoration and recovery. Such
rescue may be accomplished by reducing the rate of neu-
rofilament decrease following TBI or by enhancing and/or
stimulating the rate of neurofilament protein production and
nerve cell restoration.
The assembly of NF proteins results in the formation of
neurofilaments of approximately 10 nm in diameter in the
axon hillock that are transported down the axon. Although
their function is primarily structural, NF proteins have been
implicated in many disease processes, such as Alzheimer’s
disease (Sternbergeret al., 1985; Ulrich et al., 1987), amyo-
trophic lateral sclerosis (Troost et al., 1982), and Pick’s
disease (Pietrini et al., 1993), and in neurologic insults, such
as stroke (Arai et al., 1990, 19910; Inuzukaet al., 1990a, b;
Kaku et al., 1993; Kudo et al., 1993; Lee et al., 1991;
Nakamuraet al., 1992).
BRIEF DESCRIPTION OF THE DRAWINGS
The drawings form part of the present specification and
are included to further demonstrate certain aspects of the
present invention. The invention may be better understood
by reference to one or more of these drawings in combina-
tion with the detailed description of specific embodiments
presented herein.
FIG. 1A. Photomicrograph showing X-Gal staining in
septo-hippocampal cultures 48 hours after transfection with
cDNAfor the reporter gene, B-galactosidase. Varying ratios
of cDNAto liposomes were overlaid onto rat hippocampal
cells. Employing a 1:3 (DNA/liposome) transfection ratio,
X-Gal staining was detected in cells having neuronal mor-
phology. (Magnification: 110x).
FIG. 1B. Photomicrograph showing X-Gal staining in
septo-hippocampal cultures 48 hours after transfection with
cDNAfor the reporter gene, B-galactosidase. Employing a
1:3 (DNA/liposome) transfection ratio, X-Gal staining was
detected both in cells having astrocytic morphology.
(Magnification: 360x).
FIG. 1C. Photomicrograph showing X-Gal staining in
septo-hippocampal cultures 48 hours after transfection with
cDNAforthe reporter gene, B-Gal. Studies confirm that ratio
ofnucleic acid to liposomes during transfection is critical for
optimizing transfection efficiency. Varying ratios of cDNA
to liposomes wereoverlaid onto rat hippocampal cells. Less
efficient transfection was observed with a 1:1 transfection
ratio than that observed when a 1:3 ratio was employed
(FIG. 1A). (Magnification: 110x).
FIG. 1D. Photomicrograph showing X-Gal staining in
septo-hippocampal cultures 48 hours after transfection with
cDNAfor B-Gal. Significant toxicity was observed when




FIG. 2. B-Gal transfection efficiency calculated from
X-Gal staining in septo-hippocampal cultures at three time
points after transfection with cDNAfor B-Gal. A 1:3 ratio of
cDNAto liposomes was employed. Data are expressed as a
percentage of stained cells to the total numberofcells in ten
randomly-chosen non-overlapping fields in each of four
wells. Counts were conducted independently by two inves-
tigators. Maximaltransfection was detected two daysafter
transfection and persisted for at least one week.
FIG. 3A. RT-PCR analyses of mRNA for BDNF 1 day
after transfection of septo-hippocampal cultures employing
varying cDNA to liposome ratios. Sham transfections
employing only liposomes are also included. Total RNA
isolated from four wells was used forreverse transcription of
cDNA. To check for possible DNA contamination during
RNApreparation, the same RNA samples were included
without performing the reverse transcription procedure
(denoted by “CONTROL”). Control studies confirmed the
absence of DNA contamination. After amplification,
samples were resolved on a 1.5% agarose gels. Gels were
stained with ethidium bromide and photographed under UV
light.
FIG. 3B. RT-PCR analyses of mRNA for BDNF 1 week
after transfection of septo-hippocampal cultures employing
varying cDNA to liposome ratios. Procedures were as
described in the legend to FIG. 3A. Note that 1:4 and 2:3
ratios produced higher levels of mRNAfor BDNF one week
following transfection than produced by the 1:3 ratio. Note
also the increased level in endogenous BDNFin vitro seen
at one week in sham preparations (B) as compared to one
day post transfection (FIG. 3A).
FIG. 3C. RT-PCR analyses of mRNA for NGF one day
after transfection. After amplification, samples were
resolved on a 1.5% agarose gels. Gels were stained with
ethidium bromide and photographed under UV light.
FIG. 4A. Dark field photomicrograph of emulsion in situ
hybridization analyses of BDNF transfection in septo-
hippocampalcultures 24 hours after transfection (1:3 cDNA
to liposomesratio). Analyses employed *°P-labeled RNA
probe for BDNF. Note prominent radiolabeling superim-
posed overcell bodies. (Cell bodies are stained with hema-
toxylin in FIG. 4B).
FIG.4B. Brightfield photomicrograph of emulsion in situ
hybridization analyses of BDNF transfection in septo-
hippocampalcultures 24 hours after transfection (1:3 cDNA
to liposomes ratio). Cell bodies have been stained with
hematoxylin, and correspondto the radiodenseareas in FIG.
4A.
FIG. 5. NGF contentin cells (open bars) or culture media
(hatched bars) from control (liposomes only) and NGF-
transfected (1:3 ratio-cDNA to liposomes) septo-
hippocampal cell cultures. Data were collected 3 days after
transfection. NGF content was assayed by 2-site ELISA
employing a monoclonal antibody (clone 27/21) specific for
rat and mouse B (2.58) NGF. Data for media are expressed
as picograms per ml. Data for cells are expressed as pico-
gramsper 10° cells. Data are from pooled samples collected
from four wells.
FIG. 6A. Photomicrograph showing no X-Galstaining of
the dorsal hippocampus four days after direct intracerebral
injections of control liposomes only. (magnification: 55x).
FIG. 6B. Photomicrograph of dorsal hippocampus region
four days after direct intracerebral injections of cDNA
liposomal complexes (1:3 ratio). X-Gal positive cells have
an apparent neuronal and glial morphologyin the region of















FIG. 6C. Photomicrograph of the dorsal hippocampus
four days after direct intracerebral injections of cDNA
liposomal complexes (1:3 ratio). X-Gal positive cells have
an apparent neuronal and glial morphologyin the region of
the injection site. Injection site at the left side of the
photomicrograph. High-magnification showing staining of
cell having apparent neuronal morphology. (Magnification:
220x).
FIG. 7A. Autoradiographof in situ hybridization analyses
of expression of endogenous BDNF following sham injury.
Analyses employed **P-labeled RNA probe for BDNF.
FIG. 7B. Autoradiographofin situ hybridization analyses
of expression of endogenous BDNFthree hours after corti-
cal impact injury. Analyses employed *°P-labeled RNA
probe for BDNF. Note prominent increase in expression of
endogenous BDNF, especially in the region of the dorsal
hippocampus, as compared to sham injury animal (FIG. 7A).
FIG. 7C. Autoradiographofin situ hybridization analyses
of expression of endogenous BDNF one day following
cortical impact injury. Analyses employed *7P-labeled RNA
probe for BDNF. Note prominent increase in expression of
endogenous BDNF, especially in the region of the dorsal
hippocampus. By one day following injury, expression of
endogenous BDNFhad returned approximately to control
levels.
FIG. 8A. Expression of endogenous BDNF following
cortical impact injury. Dark field photomicrographs of emul-
sion in situ hybridization analyses of mRNA expression
employing **P-labeled cDNA probe for BDNF. Note the
increased radiolabeling overlaying cell bodies in dentate
gyrus and CA4 of the hippocampus3 hours after injury.
FIG. 8B. Expression of endogenous BDNF following
cortical impact injury. Bright field photomicrographs of
emulsion in situ hybridization analyses of mRNAexpression
employing *°P-labeled cDNA probe for BDNF. The
increased radiolabeling overlaying cell bodies in dentate
gyrus and CA4 of the hippocampusobserved in FIG. 8A is
visualized by hematoxylin staining.
FIG. 9A. TBI causes the appearance of low MW NF68
immunopositive proteins. Severe cortical impact TBI pro-
duces a decrease in the protein levels of NF68in ipsilateral
cortical samples. Associated with the loss of NF68 immu-
nostaining is the appearance of prominent lower MW bands,
which are recognized by the NF68 monoclonal. Shownis an
immunoblot of ipsilateral cortical samples from sham (S,
lane 1) and injured (I, lanes 2, 3) animals at 1 day post-
injury. Prominent 56-kDa and 52-kDa bands were observed
in cortical injured animals, but were not prominent in sham
samples. This pattern of low MW immunopositive bands
resembles the pattern of NF68 breakdown products pro-
duced by calpain-dependentproteolysis of NF68 (Kamakura
et al., 1985; Schlaepfer et al., 1984).
FIG. 9B. TBI causes the appearance of low MW NF68
immunopositive proteins. Severe cortical impact TBI pro-
duces a decrease in the protein levels of NF68in ipsilateral
cortical samples. Associated with the loss of NF68 immu-
nostaining is the appearance of prominent lower MW bands,
which are recognized by the NF68 monoclonal. Shownis the
quantitation of the appearance of NF68 breakdown products.
Immunoblots were analyzed quantitatively for total NF68
breakdown products by computer-assisted scanning densi-
tometry. Ordinate values represent arbitrary densitometric
units. The low MW immunoreactivity in sham (closed
triangles) animals did not change with time, but a dramatic
increase was seen in injured (open triangles) animals. The




FIG. 10. 6-Galactosidase transfection efficiency was cal-
culated from X-Gal staining in septo-hippocampal cultures
at 4 time points after transfection with pCMV/(-gal using 1
ug DNA/3 ul liposomes/well. Cell counts were conducted
independently by two investigators. The values represent the
mean + S.E.M.of the average numberof X-Galstained cells
in each well at 1, 2, 7, and 14 days following transfection
(n=4). B-Gal expression was maximal 2 daysafter transfec-
tion and persisted for 2 weeks.
FIG. 11A. Expression of BDNF in non-injured rats fol-
lowing transfection of liposome-BDNF cDNAcomplex (1:3
ratio) in the hippocampus. Dark field photomicrographs of
emulsion in situ hybridization analyses of mRNAexpression
employing **P-labeled cDNA probe for BDNF.
(Magnification: 110x).
FIG. 11B. Expression of BDNF in non-injured rats fol-
lowing transfection of liposome-BDNF cDNAcomplex (1:3
ratio) in the hippocampus. Bright field photomicrographs of
emulsion in situ hybridization analyses of mRNAexpression
employing 7*P-labeled cRNA probe for BDNF.
(Magnification: 110x).
FIG. 12. Photomicrograph confirming production of
BDNF protein following injection of liposome-BDNF
cDNA complex (1:3 ratio) in the dorsal hippocampus of
uninjured rats. Protein production is observed in brain cells
(note nuclei) two days following injection. (Magnification:
360x).
FIG. 13A. Quantitation of neurofilament protein decrease
following TBI. Western analysis of neurofilament protein
(NF-H)taken from a non-injured (N) and injured(I) rat two
days following cortical impact injury. Densitometric scans
of the two samples indicated a 38% decrease in NF-H levels
following cortical impact injury. (In arbitrary units, 4083
density units were recorded for the non-injured NF level,
and 2614 density units were recorded for the injured NF
level).
FIG. 13B. Quantitation of neurofilament recovery follow-
ing BDNFtransfection. Immunoreactivity of NF-H follow-
ing SDS-PAGEand Western analysis. Tissue dissected from
parietal cortex ipsilateral to the site of cortical impact.
Liposome-BDNF cDNA complex (1:3) ratio) was injected
into the ventricle ipsilateral to the injury site immediately
after injury. Increased levels of neurofilaments were
detected 2-days post-trauma in the BDNF-transfected ani-
mal (B) compared to the control animal (C) injected with
liposomesalone. (In arbitrary units, 5516 density units were
recorded for NF-H level in the injured control animal, and
5862 density units were recorded for NF-H level in the
injured BDNF-transfected animal).
DETAILED DESCRIPTION OF THE
PREFERRED EMBODIMENTS
The inventors have employed primary septo-hippocampal
cell cultures to examine liposomal-mediated gene transfec-
tion in vitro, and have determined optimalratios for trans-
fection employing the B-galactosidase reporter gene. Trans-
fection efficiency was significantly improved over the prior
art results using liposomal-mediated systemsin vitro (Kaech
et al., 1993). RT-PCR analyses have confirmed increased
expression of BDNF and NGF.Initial in situ hybridization
analyses further confirmed successful transfection of BDNF
cDNA in vitro. ELISA analyses have detected large
increases in NGFprotein after in vitro liposomal transfec-
tion. 6-Gal has been used to study transfection following
local injections of cDNA-liposome complexes in the region














liposomal mediated transfection in uninjuredrats. In order to
accurately assess the effects of gene transfection following
trauma, in situ hybridization studies have been performed to
characterize changes in endogenous NGF and BDNFafter
injury.
Liposome-mediated gene transfection of nerve growth
factor (NGF) has been exploited in primary central nervous
system cultures. RT-PCR analyses detected increased
expression of NGF mRNAonedayafter liposome-mediated
NGF gene transfection; ELISA studies detected large
increases in NGFprotein in cells and in culture medium after
NGFgenetransfection. Cells continued to secrete NGF into
the medium for at least 2 weeks. NGF bioassays confirmed
that the NGF secreted after gene transfection was biologi-
cally active.
In situ hybridization and immunohistochemistry have
demonstrated in the present invention the successful expres-
sion of NGF and BDNF mRNAat various times after
administration of cDNA-liposome complexes. Protein
expression analyses as well as immunohistochemical analy-
ses of neurotrophin receptors (p75*?**, p140°**) andbio-
activity assay of NGF and BDNF have also demonstrated
the presence of these growth factors in vitro and in vivo.
Gene therapy has been employed to achieve therapeutically
useful levels of expression of neurotrophins and other pro-
teins in the traumatically injured brain. Experimental models
of TBI have been used to facilitate the study of transfection
of central nervous system cells.
1. Forty-fold Improvementin Transfection Efficiency
Studies employing the B-Gal reporter gene in CNScell
cultures further confirmed observations of other researchers
that the concentrations of liposomes can influence the effi-
ciency oftransfection (Felgneret al., 1987). The differential
transfection efficiencies in CNScell cultures associated with
varying concentrations of liposomes is consistent with the
view that the higher the net positive charge of DNA-
liposome complexes is, the better the interaction with the
negatively charged cell membrane will be. However, overly
high levels of liposomes can cause cell lysis. Without
increasing liposome concentrations, increased amounts of
DNAdid not improve transfection efficiency.
The efficiency of the DOTMA and DOPE mediated
pCMV/B-Gal transfection observed by the inventors in
septo-hippocampalcell cultures (>1000 transfectedcells per
16 mm well) exceeds by nearly forty-fold the previously
reported transfection efficiency for B-Gal in hippocampal
cultures employing the transfection reagents Transfectam
and DOTAP (40-200 per 35mm well) (Kaechet al., 1993).
The sustained expression of B-Gal for at least two weeks
further suggests the potential therapeutic utility of liposomal
mediated gene transfection in CNS injury and degeneration.
2. 1:3 is Optimum Ratio of cDNA:Liposomesfor Transfec-
tion
B-Gal has been used as a reporter gene for examining
factors influencing the efficiency of liposome-mediated gene
transfection in central nervous system cell cultures. Results
indicate that without increasing the amounts of DNA,
increased liposome concentrations within certain limits
enhancedtransfection efficiency. However, higher liposome
levels could producecell lysis. Without increasing liposome
concentrations, increased amounts of DNA did not improve
transfection efficiency. Employing the optimal concentration
(1 ug DNAul liposomes/well), B-Gal gene expression was
sustained for at least two weeksafter transfection in primary
septo-hippocampal cultures.
Studies of liposome mediated gene transfection in septo-
hippocampal cultures determined that a concentration of 1
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ug DNA/3 ul liposomes/well (16-mm well) (or a ratio of 1:3)
produced superiorresults, and this ratio was used to transfer
the NGF gene to primary septo-hippocampal cell cultures.
The purpose of these studies was to systematically examine
if liposome-mediated NGF genetransfection could produce
increased expression of NGF mRNAandprotein. The bio-
logical activity of the NGF protein produced following
transfection was also analyzed. Ratios of cDNAto lipo-
somes were tested in the range of about 1:1 to about 1:9.
Ratios of about 1:1 to about 1:5 were particularly preferred,
with a ratio of about 1:3 being mostpreferred.
3. Successful Neurotrophin Transfection in Vitro and in Vivo
Gene transfection could result in increased expression of
trophic proteins or decreased expression of toxic proteins.
Routes of administration of liposomal-cDNA complexes
could include direct delivery into the central nervous system
(local, ventricular, and/or epidural injections) or systemic
injections. Specific tissues and cell types could be targeted
by several approaches. These include using promoter
enhancer elements that are tissue and cell type specific,
administration of the plasma regionally into selected tissue
compartments as indicated above and coupling a targeting
ligand to the liposomal surface.
4. BDNF and NGF Transfection Rescues Neurofilament
Loss After TBI
A post-injury analysis of neurofilament proteins in the
cortex and hippocampaltissue was performed. Lateral cor-
tical impact injury resulting in severe TBI causes pro-
nounced reduction in NF68 and NF200 levels that lasts for
at least 2 weeks post-injury. Further, the presence of low
molecular weight (MW) NF68 immunopositive bands of 52
kDa and 56 kDa mayindicate the involvement of calpain-
mediated proteolysis. The temporal and regionalprofiles of
these changes could have profound implications for axonal
and dendritic pathology after severe TBI.
Primary septo-hippocampal cell cultures have been
employed to demonstrate the therapeutic potential of BDNF
gene transfection in facilitating the recovery of neurofila-
ment loss caused by depolarization injury. Employing a
pUC19-based plasmid, rat BDNF cDNAwassubcloned into
a unique NotI site under the control of the CMV promoter
to generate pBDNF. DNA for BDNF was complexed with
liposomes and transfected into primary septo-hippocampal
cell cultures one day after depolarization injury (6.0 min
depolarization with 60 mM KC]and the presence of 2.8 mM
Ca**). Three days after depolarization injury, Western blot
and immunohistochemical analyses detected significant loss
(42%) of NF-M and NF-H proteins (Sternberger SMI 31
antibody) in untreated cultures. However, densitometric
scanning of Western blot data indicated that BDNFtrans-
fection produced a two-fold increase in NF-M/NF-Hthree
days following injury as compared to untreated cultures.
Immunohistochemical studies also detected enhanced
NF-M/NF-H immunolabeling in injured neurons following
BDNFtransfection as compared to untransfected, injured
controls. Thus, BDNF gene transfection could be a useful
therapeutic tool for blunting neurofilament loss associated
with injury to central nervous system neurons.
5. Use of the Cytomegalovirus Promoter
When the gene remains extrachromosomal, as in liposo-
mal mediated gene transfections, optimal levels of expres-
sion are likely to be achieved using viral promoters.
Furthermore, viral promoters generally function in a broad
range of cell types. The relative strengths of several com-
monly used viral promoters have been studied in different
cell lines including primary cultures of rat mammary epi-














and human hepatocytes (Fang et al., 1989; Li et al., 1992),
human embryofibroblasts (Giordanoet al., 1991) and brain
tumorcell lines (Dellig and Seliger, 1990). Studies indicate
that the cytomegalovirus is a prudentinitial choice of viral
promoter. In primary cultures of human hepatocytes, the
CMVpromoter yields a higher transfection efficiency than
RSV and SV40 (Li et al., 1992). RSV and CMVpromoters
were tested for activity are substantial in non-replicating
cells: the efficiency of RSV promoter is not greater than
background whereas the CMV promoter is very active.
Furthermore, the CMV promoter exhibits two-fold greater
activity in growing cells (Giordanoet al., 1991). The CMV
promoter also showshigh activity in glioblastomacell lines
(Dellig and Seliger, 1990).
6. Immunocytochemistry of NGF and BDNF
RT-PCR and in situ hybridization techniques may be
employed to determinethe transfection efficiencies for NGF
and BDNF. Autoradiographic and emulsion in situ hybrid-
ization techniques employ **P-labeled mRNA probes for
NGF and BDNFto provide information on the regional
extent, cellular localization and persistence of increased
mRNA. RT-PCR methods provide semiquantitative infor-
mation on changes in mRNA. RT-PCRtechniques are con-
siderably more sensitive than Northern blots and are more
robustto the effects of injury. RT-PCRhasbeenreliably used
to evaluate levels of NGF and BDNF mRNAin rodentbrains
(Giordano et al., 1992). In situ hybridization studies are
important for development of appropriate dissection proto-
cols for TR-PCRanalysesin vivo, since, in vivo transfection
will be restricted to specific areas of the brain.
A monoclonal antibody (clone 27/21) specific for rat and
mouse 6 (2.5S) NGFthat is also suitable for ELISA deter-
minations of NGF proteins in brain tissue was used for
protein assessment. An antibody for BDNF having consid-
erable specificity has been reported (Denton et al., 1993),
and Dr. Franz Hafti of Genentech, Inc. provided this anti-
body. Immunohistochemistry may be employed to describe
regional changes in expression of NGF and BDNFprotein.
ELISA maybe used to provide quantitative data on changes
in neurotrophin protein levels.
Immunohistochemical analyses of neurotrophin receptors
p7SXOFR, 140°, p145°*8 may be performed. Antibodies
are made to synthetic peptide segments on the different
receptors and allow determination of different tyrosine
kinase receptors (TRKs) as well as differential staining of
full and truncated versions of the different TRKs. Neurotro-
phins bind with equal affinity to a common low affinity
neurotrophin receptor, p75“whose functionis likely to
be stimulation of high affinity binding to trk receptors (Chao
et al., 1993, Battlemanet al., 1993).
The different neurotrophins also bind to different mem-
bers of the trk family of membrane-spanning tyrosine kinase
receptors, the signal transducing elements of the neurotro-
phins (Barker and Murphy, 1992). NGFbindsspecifically to
p140"*. BDNFbindsspecifically to p145°". NT-3 binds to
both p145’ and p145”*. Although there are claims that
p140"* by itself has high affinity NGF-binding properties,
others report that both genes are required for high affinity
NGF-binding activity (Chao et al., 1993, Battleman etal.,
1993).
7. Biological Functional Equivalents
As mentioned above, modification and changes may be
made in the structure of a neurotrophic gene and still obtain
a functional molecule that encodes a protein or polypeptide
with desirable characteristics. The following is a discussion
based upon changing the amino acids of a protein to create
an equivalent, or even an improved, second-generation
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molecule. The amino acid changes may be achieved by
changing the codons of the DNA sequence, according to the




Alanine Ala A GCA GCC GCG GCU
Cysteine Cys C UGC UGU
Aspartic acid Asp D GAC GAU
Glutamic acid Glu E GAA GAG
Phenylalanine Phe F UUC UUU
Glycine Gly G GGA GGC GGG GGU
Histidine His H CAC CAU
Isoleucine Tle I AUA AUC AUU
Lysine Lys K AAA AAG
Leucine Leu L UUA UUG CUA CUC CUG CUU
Methionine Met M AUG
Asparagine Asn N AAC AAU
Proline Pro P CCA CCC CCG CCU
Glutamine Gln Q CAA CAG
Arginine Arg R AGA AGG CGA CGC CGG CGU
Serine Ser S AGC AGU UCA UCC UCcG UCU
Threonine Thr T ACA ACC ACG ACU
Valine Val V GUA GUC GUG GUU
Tryptophan Trp W UGG
Tyrosine Tyr Y UAC UAU
 
For example, certain amino acids may be substituted for
other amino acids in a protein structure without appreciable
loss of interactive binding capacity with structures such as,
for example, antigen-binding regions of antibodies or bind-
ing sites on substrate molecules. Since it is the interactive
capacity and nature of a protein that defines that protein’s
biological functional activity, certain amino acid sequence
substitutions can be made in a protein sequence, and, of
course, its underlying DNA coding sequence, and neverthe-
less obtain a protein with like properties. It is thus contem-
plated by the inventors that various changes may be made in
the DNA sequences of neurotrophic genes without appre-
ciable loss of their biological utility or activity.
In making such changes, the hydropathic index of amino
acids may be considered. The importance of the hydropathic
aminoacid index in conferring interactive biologic function
on a protein is generally understood in the art (Kyte &
Doolittle, 1982, incorporate herein by reference). It is
accepted that the relative hydropathic character of the amino
acid contributes to the secondary structure of the resultant
protein, which in turn defines the interaction of the protein
with other molecules, for example, enzymes, substrates,
receptors, DNA, antibodies, antigens, and the like.
Each amino acid has been assigned a hydropathic index
on the basis of their hydrophobicity and charge character-
istics (Kyte & Doolittle, 1982), these are: Isoleucine (+4.5);
valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/
cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine
(-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9);
tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate
(-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5);
lysine (-3.9); and arginine (-4.5).
It is known in the art that certain amino acids may be
substituted by other amino acids having a similar hydro-
pathic index or score andstill result in a protein with similar
biological activity, i.e., still obtain a biological functionally
equivalent protein. In making such changes,the substitution
of amino acids whose hydropathic indices are within +2 is
preferred, those which are within +1 are particularly
preferred, and those within +0.5 are even more particularly
preferred.
It is also understoodin theart that the substitution oflike












philicity. U.S. Pat. No. 4,554,101, incorporated herein by
reference, states that the greatest local average hydrophilic-
ity of a protein, as governed by the hydrophilicity of its
adjacent amino acids, correlates with a biological property
of the protein.
As detailed in U.S. Pat. No. 4,554,101, the following
hydrophilicity values have been assigned to amino acid
residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0+1);
glutamate (+3.0#1); serine (+0.3); asparagine (+0.2);
glutamine (+0.2); glycine (0); threonine (-0.4); proline
(-0.5+1); alanine (-0.5); histidine *-0.5); cysteine (-1.0);
methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine
(-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan
(-3.4)
It is understood that an amino acid can be substituted for
another having a similar hydrophilicity value andstill obtain
a biologically equivalent, and in particular, an immunologi-
cally equivalent protein. In such changes,the substitution of
amino acids whose hydrophilicity values are within +2 is
preferred, those which are within +1 are particularly
preferred, and those within +0.5 are even more particularly
preferred.
As outline above, amino acid substitutions are generally
therefore based on the relative similarity of the amino acid
side-chain substituents, for example, their hydrophobicity,
hydrophilicity, charge, size, and the like. Exemplary substi-
tutions which take various of the foregoing characteristics
into consideration are well knownto those of skill in the art
and include: arginine and lysine; glutamate and aspartate;
serine and threonine; glutamine and asparagine; and valine,
leucine and isoleucine.
8. Site-Specific Mutagenesis
Site-specific mutagenesis is a technique useful in the
preparation of individual peptides, or biologically functional
equivalent proteins or peptides, through specific mutagen-
esis of the underlying DNA. The technique further provides
a ready ability to prepare and test sequence variants, for
example, incorporating one or more of the foregoing
considerations, by introducing one or more nucleotide
sequence changes into the DNA.Site-specific mutagenesis
allows the production of mutants through the use of specific
oligonucleotide sequences which encode the DNA sequence
of the desired mutation, as well as a sufficient number of
adjacent nucleotides, to provide a primer sequence of suf-
ficient size and sequence complexity to form a stable duplex
on both sides of the deletion junction being traversed.
Typically, a primer of about 17 to 25 nucleotides in length
is preferred, with about 5 to 10 residues on both sides of the
junction of the sequence being altered.
In general, the technique of site-specific mutagenesis is
well knownin the art, as exemplified by various publica-
tions. As will be appreciated, the technique typically
employs a phage vector which exists in both a single
stranded and double stranded form. Typical vectors useful in
site-directed mutagenesis include vectors such as the M13
phage. These phage are readily commercially available and
their use is generally well knownto those skilled in theart.
Double stranded plasmids are also routinely employed in
site directed mutagenesis which eliminates the step of trans-
ferring the gene of interest from a plasmid to a phage.
In general, site-directed mutagenesis in accordance here-
with is performedbyfirst obtaining a single-stranded vector
or melting apart of two strands of a double stranded vector
which includes within its sequence a DNA sequence which
encodes the desired neurotrophic protein. An oligonucle-
otide primer bearing the desired mutated sequence is
prepared, generally synthetically. This primer is then
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annealed with the single-stranded vector, and subjected to
DNApolymerizing enzymes such as FE. coli polymerase I
Klenow fragment, in order to complete the synthesis of the
mutation-bearing strand. Thus, a heteroduplex is formed
wherein one strand encodes the original non-mutated
sequence and the second strand bears the desired mutation.
This heteroduplex vector is then used to transform appro-
priate cells, such as E. coli cells, and clones are selected
which include recombinant vectors bearing the mutated
sequence arrangement.
The preparation of sequence variants of the selected
neurotrophic gene using site-directed mutagenesis is pro-
vided as a meansof producing potentially useful species and
is not meantto be limiting as there are other ways in which
sequence variants of neurotrophic genes may be obtained.
For example, recombinant vectors encoding the desired
neurotrophic gene may be treated with mutagenic agents,
such as hydroxylamine, to obtain sequence variants.
In certain embodiments, it will be advantageous to
employ nucleic acid sequences of the present invention in
combination with an appropriate means, such asa label, for
determining hybridization. A wide variety of appropriate
indicator means are knownin theart, including fluorescent,
radioactive, enzymatic or other ligands, such as avidin/
biotin, which are capable of giving a detectable signal. In
preferred embodiments, one will likely desire to employ a
fluorescent label or an enzyme tag, such as urease, alkaline
phosphatase or peroxidase, instead of radioactive or other
environmental undesirable reagents. In the case of enzyme
tags, calorimetric indicator substrates are knownthat can be
employed to provide a meansvisible to the human eye or
spectrophotometrically, to identify specific hybridization
with complementary nucleic acid-containing samples.
In general, it is envisioned that the hybridization probes
described herein will be useful both as reagents in solution
hybridization as well as in embodiments employing a solid
phase. In embodiments involving a solid phase, the test
DNA(or RNA)is adsorbedor otherwise affixed to a selected
matrix or surface. Thisfixed, single-stranded nucleic acid is
then subjected to specific hybridization with selected probes
under desired conditions. The selected conditions will
depend on the particular circumstances based on the par-
ticular criteria required (depending, for example, on the
G+C content, type of target nucleic acid, source of nucleic
acid, size of hybridization probe, etc.). Following washing
of the hybridized surface so as to remove nonspecifically
bound probe molecules, specific hybridization is detected, or
even quantitated, by means ofthe label.
The following examples are included to demonstrate
preferred embodiments of the invention. It should be appre-
ciated by those of skill in the art that the techniques
disclosed in the examples which follow represent techniques
discovered by the inventors to function well in the practice
of the invention, and thus can be considered to constitute
preferred modesfor its practice. However, those of skill in
the art should, in light of the present disclosure, appreciate
that many changes can be madein the specific embodiments
which are disclosed andstill obtain a like or similar result
without departing from the spirit and scope of the invention.
EXAMPLE1
OPTIMIZING IN VITRO TRANSFECTION
EFFICIENCY USING 6-GAL
Previous work has shownthat the ratio of nucleic acid to
liposomesduring transfection is critical for optimizing trans-














100 ul Dulbecco’s Modified Eagle medium (D-MEM) was
mixed with 1 wl or 3 wl of cationic liposomes diluted in 100
i D-MEM,and overlaid overnight onto rat hippocampal
cells, 80 to 90% confluent (2.8x10° cells per 15 mm plate).
X-Gal staining was performed 48 hours after transfection to
calculate transfection efficiency. Employing a 1:3 (DNA/
liposome) transfection ratio, X-Gal staining was detected
both in cells having neuronal and astrocytic morphology
(FIG. 1A).
Lessefficient transfection was observed with a 1:1 trans-
fection ratio (FIG. 1B vs. FIG. 1C). Employing a 1:3 ratio
of cDNAto liposomes, B-Gal transfection efficiency was
calculated from X-Gal staining and septo-hippocampalcul-
tures at three time points after transfection with cDNA for
the reporter gene, B-Gal (FIG. 2). Maximal transfection
(>3%) was detected two days after injury and persisted for
at least one week.
The efficiency of transfection of B-Gal observed in cul-
tured hippocampal neurons (>3%) far exceeds previously
reported transfection efficiency for B-Gal in hippocampal
cultures employing transfection reagents Transfectam and
DOTAP (<0.02%) (Kaech et al., 1993). The differential
efficiencies associated with varying ratios of cDNA to
liposomesis consistent with the view that the higher the net
positive charge of DNA-liposomes complexes,the better the
interaction with a negatively charged cell membrane.
EXAMPLE 2
IN VITRO NGF AND BDNF TRANSFECTION
Employing transfection procedures described herein (see
Example 1), RT-PCR™ analyses were performed using
mRNA for BDNF one day and one weekafter transfection
of septo-hippocampal cultures employing varying cDNAto
liposome ratios (FIG. 3A, FIG. 3B, and FIG. 3C). Sham
transfections employing only liposomes were also included.
Total RNA isolated from each well was used for reverse
transcription for cDNA. To check for possible DNA con-
tamination during RNApreparation, the same RNA samples
were included without performing the reverse transcription
procedure. RT-PCR confirmed increased message for BDNF
for all ratios tested, as compared to sham transfections.
Control studies confirmed the absence of DNA contamina-
tion.
FIG. 3B showsthat 1:4 and 2:3 ratios produced higher
levels of mRNA for BDNF one week following transfection
than produced by the 1:3 ratio. The inventors also observed
increased levels in endogenous BDNFin vitro seen at 1
week in sham transfected preparations (FIG. 3B) and com-
pared to 1 day after sham transfection (FIG. 3A). RT-PCR
analyses also confirmed increased mRNA for NGF one day
after transfection (FIG. 3C). Preliminary in situ analyses
employing **P-labeled RNA probe for BDNFalso detected
prominent radiolabeling (FIG. 4A) superimposed overcell
bodies stained with hematoxylin (FIG. 4B).
ELISA studies have detected dramatic increases in NGF
protein both in cells and media 3 daysafter transfection of
septo-hippocampal cultures (FIG. 5). These large increases
in NGFindicate that transfected cells are not only producing
NGFbutalso releasing the protein into the culture medium.
The observation of similar profiles of neurotrophin produc-
tion in vivo would strongly suggest that transfection of
neurotrophin genes would have therapeutic potential in the
intact animal.
EXAMPLE3
B-GAL TRANSFECTION EFFICIENCY IN VIVO
USING UNINJURED RATS
As shown in FIG. 6, the present invention provides
evidence that direct intracerebral injections of cDNA:lipo-
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somal complexes (1:3 ratio) into the dorsal hippocampus of
uninjured rats can produce transfection of the §-Gal reporter
gene four days after injection. Initial microscopic analyses
indicate X-Gal staining in cells having apparent neuronal
and glial morphology.
EXAMPLE4
NGF AND BDNF EXPRESSION IN SHAM
INJURED AND INJURED RATS
In studies of transfection of BDNF and NGFfollowing
TBI, it is important to describe the effects of injury on
expression of endogenous BDNF and NGF.In situ hybrid-
ization analyses of expression of endogenous BDNF have
been performed following sham injury (FIG. 7A), 3 hours
after cortical impact injury (FIG. 7B), or 1 day following
cortical impact injury (FIG. 7C). Cortical impact injury
produced prominent increases in expression of endogenous
BDNF,especially in the region of the dorsal hippocampus,
as compared to sham injury controls. By 1 day following
injury, expression of endogenous BDNF had returned
approximately to control levels. Emulsion in situ hybridiza-
tion analyses have been utilized to provide detail on the
cellular localization of changes in expression of endogenous
BDMFthree hours following cortical impact injury (FIG. 8A
and FIG. 8B). These studies detected increased radiolabeling
primarily localized over cell bodies in regions such as the
dentate gyrus and CA4of the hippocampus.
EXAMPLE5
CONSTRUCTION OF VECTORS AND
LIPOSOME FORMULATION
The cytomegalovirus (CMV) promoter (Fang et al., 1989;
Giordanoet al., 1991; Li et al., 1992; Thompsonet al., 1993)
was incorporated into a pUC19-derived expression vector
for construction of the NGF and BDNFtransfection vectors
(pNGF and PBDNF,respectively) (MacGregor and Caskey,
1989; Yang et al., 1994a). The rat NGF and BDNF cDNAs
were subcloned individually into a unique NotI site under
the control of the CMV promoter. The BDNF and NGF
genes were obtained from C. Y. Hsu, Department of
Neurology, Washington University School of Medicine, St.
Louis, Mo.
A commercially available, 1:1 (w:w) mixture of the
cationic lipid n-[1-(2,3-dioleyloxy)propyl]-N,N,N-
trimethylammonium chloride (DOTMA)and dioleoyl phos-
photidylethanolamine (DOPE) was used for the liposome
formulation and was prepared in membrane-filtered water
(GIBCO-BRL, Bethesda, Md.).
EXAMPLE6
EXPRESSION OF mRNA FOLLOWING
TRANSFECTION
1. RT-PCR analyses of NGF and BDNF mRNA
1 day after liposome-mediated NGF or BDNF gene
transfection (1 ug DNA/3 zal Liposomes/well),cells in culture
were lysed by adding 0.2 ml of RNAzol B (Cinns/Biotec
Laboratories, Inc.) per 10° cells. The RNApreparations were
performed as previously described (Yanget al., 1993). Total
RNAfrom individual wells was used for DNA synthesis at
42° C. for 2 h using 200 units of M-MLV reverse tran-
scriptase (Perkin-Elmer, Norwalk, Conn.), 40 nmol of
dNTT, 200 mmol DTT and using oligo-dT as primers.
Increased NGF (FIG. 5) or BDNF(FIG.11A and FIG. 11B)














cells, respectively as compared to sham transfections. To
check for possible DNA contamination during RNA
preparation, RNA samples were included without perform-
ing reverse transcription; no DNA was detected in these
control samples.
For PCR™, one pair of forward and reverse primers of
NGF were used. The sequence of NGF/S primer was
5'-GGCATGCTGGACCCAAGCTC-5' (SEQ ID NO:3), and
of NGF/3, was 5'-GCGCTTGCTCCGGTGAGTCC-3' (SEQ
ID NO:4) (Giordanoet al., 1991). Total DNA and 40 pmol
of primer were used for PCR™. PCR™wascarried out in
a programmable bearing block (Perkin-Elmer, Norwalk,
Conn.) using cycles consisting of denaturation at 95° C. for
1 min, followed by annealing at 35° C. for 1 min, and DNA
extension at 72° C. for 2 min (Yanget al., 1993).
After 25 cycles of PCR™, samples were electrophoresed
on 1.5% agarose gels. Gels were stained with ethidium
bromide and photographed under UV light. NGF mRNA
expression was increased in NGF DNA-transfected cultures
compared to liposome-only treated cultures, and medium-
only control cultures. The 100-bp DNAladder from Gibco
BRL (Grand Island, N.Y.) was used as molecular weight
markers.
Because of interest in injury mechanisms in the hippoc-
ampusand the preferential vulnerability of the hippocampus
to traumatic or ischemic brain injury (Jenkins et al., 1989;
Lyeth et al., 1990), mixed primary septo-hippocampalcell
cultures were used for in vitro studies of liposome-mediated
gene transfection. Cultures were incubated for one week
prior to transfection. By is that time, astrocytes reached
confluence and were no longer actively multiplying, while
neurons were well differentiated and stable.
2. ELISA Analysis of NGF Protein
NGF protein levels were examined two days after
liposome-mediated NGF transfection using an antibody-
sandwich ELISA assay. NGF concentrations were quantified
against a standard concentration curve of pure isolated
murine NGF. Cells were treated with lysis buffer and
extracted on ice for 10 min. Extractions were centrifuged at
20,000xg for 15 min at 4° C. Wells were coated with 0.25
ug/ml anti-NGF antibodies (Boehringer Mannheim Corp.,
Ind.). A standard NGFdilution series was prepared. Diluted
homogenate or medium (100 yl) and standard NGFdilutions
(100 wl) were added to the antibody-coated wells and
incubated overnight at 4° C. After washing the plate with
water and blocking buffer, antibody-B-Gal-conjugate solu-
tion (100 wl) was added to each well and incubated (4 hat
37° C.). After another wash with blocking buffer, substrate
solution (200 ul) was added to each well and incubated (37°
C. for 2 h). Plates were read at 570 nm. A graph of these
results showed significant (P<0.01) increases in NGF pro-
tein in septo-hippocampal cultures 2 days after transfection
(values represent means=S.E.M.; n=4). These studies
detected dramatic increases in NGF protein in cell pallets
from transfected septo-hippocampalcultures.
Three days after NGF genetransfection, robust increases
of NGF protein were detected by ELISA in the cell culture
medium. The secreted form of NGF in the medium could
still be detected two weeks after pNGFtransfection. Since
weroutinely exchange the medium 3 time a week after gene
transfection, the consistent detection of the secreted form of
NGFin the medium suggests that septo-hippocampal cells
express and secrete NGF for at least two weeks after
liposome-mediated gene transfection.
ELISAanalysis of NGF protein in culture medium: Three
days after NGF gene transfection, NGF protein was
increased ten fold in the medium from NGF DNAtrans-
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fected cultures. Increased secreted NGF could be detected in
the medium two weeks after NGF DNAtransfection (values
represent means=S.E.M.; n=4). The medium was exchanged
3 times a week after gene transfection.
3. PC12 Confirmed NGF Activity Following Transfection
Rat pheochromocytoma (PC12) cells were used to con-
firm the specific biological activity of NGF in medium
conditioned by cell cultures transfected with NGF DNA.
PC12 cell medium was removedthree hours after plating, a
sufficient amount of time for cells to attach to wells, and
replaced with 0.5 ml of conditioned medium collected from
cultures three days following liposome-mediated NGF DNA
transfection. NGF (20 ng/ml) was added to sister wells to
assay the cells’ response to exogenous NGF. Thirty-three
hours later, cells were observed for the presence of neurite
outgrowth. The secreted form of NGF in the NGF DNA
transfected cell medium produced biological effects similar
to those of NGF isolated from mouse submaxillary gland.
However, medium from control cells incubated only with
liposomes did not produce neurotrophic effects.
Assay of bioactivity of NGF: representative photomicro-
graphs of changes in PC12 cell morphology after 33 h in
conditioned media from primary septo-hippocampal cul-
tures. Rat PC12 cells were plated on a 24-well plate (pre-
coated with 50 ug/ml poly-D-lysine in RPM-1640 culture
medium at a density of 2x10° cell/0.5 ml). Prominent
neuritic outgrowth and associated growth cones were pro-
duced by the medium from NGF DNAtransfected cultures.
These results were similar to those obtained following
administration of exogenous NGF.
These results represent the first reported use of liposome-
mediated NGFtransfection in post-mitotic central nervous
system cell cultures. The levels of NGF protein expressed in
our transfection system are particularly high, persist for at
least 14 days andelicit prominent neurotrophic effects such
as neurite growth and growth cone formation. Thepersistent
secretion of large amounts of NGF in media after pNGF
transfection suggests the potential utility of neurotrophin





Hippocampal and septal neurons are prepared from the
brain of 18-day old Sprague-Dawley rat fetuses using the
method of Banker and Cowan (1977) (Banker and Cowan,
1977), but without trypsinization. After washing thecells are
dissociated by repeated passage through a flame constricted
Pasteur pipette, collected by centrifugation, resuspended in
D-MEM supplemented with 10% fetal calf serum and then
plated on poly-L-lysine coated 24-well plates (1.09x10°
cells/well). Cells for in situ hybridization are plated simi-
larly but in 8-well Nunc Lab-tek chamberslides. Cultures
are kept in a humidified CO, incubatorat 37° C. After 5 days
of culture the media is changed into DMEM-based B18
medium (Brewer and Cotman, 1989). Subsequent media
replacement is carried out twice a week. Cultures are
allowed at least one week of incubation priorto transfection.
Bythat time, astrocytes have reached confluence and are no
longer actively multiplying, while neurons are well differ-
entiated and stable.
EXAMPLE8
IN VIVO TRANSFECTION FOLLOWING TBI
USING RODENT MODELS
Two models of traumatic brain injury have been devel-














injects a small volume of saline epidurally into the close
cranial cavity of rats (Dixonet al., 1987). The inventors have
employedthis device to model moderate diffuse brain injury.
The second model of brain injury employs pneumatically
controlled impact to the exposed cortical surface of rats
(Dixon et al., 1991). The inventors employ this device to
model severe head injury associated with mass lesions and
greater frequency of diffuse axonal injury than observed
with the fluid percussion device.
Both of these devices have been used to examine the
effects of varying severities of traumatic brain injury on gene
transfection. Both of these models were developed in the
inventors’ laboratories and have been widely employed by
investigators of central nervous system trauma.
1. Fluid Percussion Injury
Animals are surgically prepared for fluid percussion
injury under sodium pentobarbital anesthesia (54 mg/kg,
ip.) 48 hours prior to trauma (for details, see Dixon et al.,
1987). Surgical procedures are performed understerile con-
ditions in a laboratory site dedicated to rat surgery. A
4.8-mm diameter craniotomy is performed overthe sagittal
suture midway between lambda and bregma. Twostainless-
steel skull screws (2-56x9.5 mm)are placed into burr holes
1 m rostral to bregma and 1 mm caudal to lambda.
Arigid plastic injury tube (modified Leur-loc syringe hub,
2.6 mm inside diameter) is placed over the exposed dura and
bonded to the skull with cyanoacrylate adhesive. Dental
acrylic is then poured around the injury tube and skull
screws and the tube is then sealed with Gelfoam. The scalp
is sutures closed and Bacitracin ointment is applied over the
incision. Animals are returned to their home cage (one
animal per cage) after they have recovered from anesthesia.
All rats are anesthetized with isoflurane (4%) and a 2:1
N,0/O, mixture prior to injury. Animals will be observed
for the presence of convulsions and apnea. Core body
temperature is monitored using a rectal probe and main-
tained at 37°—38° C. The fluid percussion device consists of
a Plexiglas cylindrical reservoir bounded at one end by a
Plexiglas piston mounted on O-rings. The entire system is
filled with isotonic saline. Injury is induced bythe decent of
a metal pendulum striking the piston. This injects a small
volume of saline epidurally into the closed cranial cavity,
producing a brief displacement and deformation of neural
tissue. The resulting pressure pulse is monitored on a storage
oscilloscope (Textronix 5111).
2. Cortical Impact Injury
The injury device was modified from similar devices
developed at the Biomedical Science Department of the
General Motors Research Laboratories in Warren, Mich. The
pneumatic impactor consists of a small (1.975 cm) bore,
double-acting, stroke-constrained, pneumatic cylinder with
a 5.0 cm stroke (for details, see Dixon et al., 1991). The
cylinderis rigidly mounted on a crossbar. The lower rod end
has an impactor tip attached. The upper rod end is attached
to the transducer core of a linear velocity differential trans-
former (LVDT) (Shaevitz Model 500 HR). The impact
velocity can be adjusted by controlled gas pressure. Impact
velocity is directly measured by the LVDT which produces
an analog signal that is recorded for analysis of time/
displacement parameters of the impact.
All animals are initially anesthetized with 4% isoflurane
and a 2:1 N,0/O, mixture. Following endotracheal
intubation, rats are mechanically ventilated with a 2% isof-
lurane mixture. The rats are mounted in the injury device’s
stereotaxic frame. A midline incision is made, soft tissues
reflected, and a craniectomy performed. Core body tempera-
ture is monitored continuously by a rectal thermistor probe




DETERMINATION OF TIME COURSE OF
TRANSFECTION
To determine the time course of transfection, in situ
hybridization and immunohistochemical studies of the dor-
sal hippocampus is performed following control injections
of liposomesalone andat one day, three days, one week, one
month, two months and three months following injections of
optimal ratios of cDNA to liposomes for NGF and BDNF.
Based on regional analyses, RT-PCR and ELISAstudies are
conducted at selected time points. At these same selected
time points, immunohistochemical analyses of neurotrophin
receptors (p75°"*, p140°™, p145”**) andassay bioactiv-
ity of NGF and BDNFare also performed. The inventors’
choice of time points was based on the observation that
liposome mediated gene transfection is transient and has




NEUROFILAMENT PROTEINS IN MIXED
SEPTO-HIPPOCAMPAL CULTURES
Chronic (3-6 hour) potassium depolarization of cultured
neurons enhances maturation of the neuronal cytoskeleton.
However, traumatic brain injury, which is accompanied by
transient (~3 min.) potassium depolarization produces sig-
nificant cytoskeletal degradation including loss of axonal NF
protein. To investigate the effect of short-term depolarization
on neurofilament proteins and determine calcium’s role in
that effect, mixed septo-hippocampal cultures were exposed
for 6 min. to 60 mM KClin the presence of Ca** concen-
trations from 1.8 to 5.8 mM.Cultures were depolarized at 10
days in vitro when neuronal arborization was extensive and
astrocytes were confluent. At 9 to 10 days after
depolarization, cultures were lysed and homogenates were
analyzed via SDS-PAGE Western blotting for alterations in
NF150 and NF68. 2-D densitometry was used for quantita-
tion.
Neurofilament proteins were decreased in all treated cul-
tures. Initial results indicate levels returned to normal by 10
days after insult following treatment with up to 2.8 mM
Ca**. This decrease was Ca**-dependent and exhibited
different time courses for the two proteins examined. Thus,
short-term depolarization can temporarily decrease levels of
neurofilament proteins. Ca*t-dependent disruption of the
axonal cytoskeleton mayplay a role in the reversible func-
tional deficits observed in rat models of traumatic brain
injury.
EXAMPLE11
NEUROFILAMENT 68 AND NEUROFILAMENT
200 PROTEIN LEVELS DECREASE AFTER
TRAUMATIC BRAIN INJURY
A. MATERIALS AND METHODS
1. Cortical Impact and Tissue Dissection Nine groups
(n=6-8 per group) of male Sprague-Dawley rats (250-350
g) were used in this study. Groups included naive animals
and the following post-injury groups: sham 3 h,injured 3 h,
sham 1 day, injured 1 day, sham 7 days, injured 7 days, sham
14 days, and injured 14 days. For induction of severe TBI,
a controlled cortical impact device described previously
(Dixonet al., 1991) wasutilized. Briefly, rats were intubated













N,0/O,. Two 7 mm diameter craniotomies were performed
adjacent to the central suture, midway between lambda and
bregma. The dura was kept intact. Injury was induced by
impacting the right exposed cortex with a 6 mm diametertip
at a rate of 6 m/sec and a 2 mm compression (Dixonet al.,
1991). Sham-injured animals underwent identical surgical
procedures but did not receive impact injury. Following
cortical impact, animals were extubated and immediately
assessed for recovery of reflexes (Dixon et al. 1991).
Animals whoserighting response did not exceed 5 min were
omitted from the study.
Following assessmentandat the appropriate timeinterval,
animals were killed under halothane anesthesia and imme-
diately prepared for tissue microdissection. Sections of the
hippocampusand cortex directly beneath and craniotomies
were removed. Cortex was selected for study because,
ipsilaterally, it is the locus of injury, and contralaterally, it
may represent a contre coup damagesite resulting from
tissue extrusion at impact (Meaneyet al., 1992). The under-
lying hippocampal tissue was examined because of its
established preferential vulnerability after TBI (Hayeset al.,
1992; Taft et al., 1992). The dorsal hippocampus was
microdissected bilaterally. Excision of the parietal cortices
beneath the craniotomies extended approximately 4 mm
laterally, approximately 7 mm rostrocaudally, and to a depth
extending to the white matter. All tissue was frozen imme-
diately in liquid N,.
2. Sample Processing and Gel Electrophoresis
The microdissected tissue homogenized at 4° C. in an
ice-cold homogenization buffer containing 20 mM PIPES
(pH 7.1), 2 mM EGTA, 1 mM EDTA, 1 mMdithiothreitol,
0.3 mM phenylmethylsulfonylfluoride (PMSF), and 0.1 mM
leupeptin. The presence of chelators and protease inhibitors
prevents endogenous in vitro activation of proteases and
subsequent artifactual degradation of the NF proteins in
vitro. Proteins were assessed for concentration by the Brad-
ford procedure (Bradford, 1976) and balanced for protein
content. Samples were then solubilized by 2;1 dilution in
sodium dodecyl sulfate (SDS)-containing stop solution (600
mM Tris, 200 mM EDTA, 10% sucrose, 3% SDS) and
heated for 5 min at 85° C. Proteins were reduced with
6-mercaptoethanol and resolved by SDS polyacrylamide gel
electrophoresis (PAGE). A vertical electrophoresis chamber
using a 4.5% acrylamide stacking gel over 6% acrylamide
resolving gel was routinely employed. Typically, 50-75 ug
of sample protein were run in each lane at constant current
(120 mA)for 2.5 h. All sample lanes on each gel contained
identical amounts of protein. To insure consistency of gel
loading,silver staining of identical sister gels was performed
and Ponceau red staining of each blot was conducted prior
to immunolabeling. To minimize gel-to-gel comparisons,
time course gels were routinely performed to observe NF
changes post-injury with all sampling times contained on a
single gel.
3. Quantitative Immunoreactivity of NF68 and NF200
Immediately after separation of the proteins by SDS-
PAGE,proteins were transferred to nitrocellulose membrane
by Western blotting technique (Towbin etal., 1979). Lateral
transfer was conducted between twoplate electrodes and a
transfer buffer containing 62.5 mM glycine, 50 mM Tris, and
10% methanol wasutilized. Transfer occurred at a constant
current of approximately 365 mA at 4° C. Incubation in
primary antibody was performed with either anti-NF68
(Sigma N5139) or anti-NF200 (Sigma N0142) monoclonal
antibodies.
NF68 and NF200 were chosen for analysis because they
are, respectively, the most important structural and cross-
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linking elements of neurofilaments. Both monoclonals rec-
ognize phosphorylated and non-phosphorylated neurofila-
ment epitopes. Visualization was performed with an avidin-
alkaline phosphate kit using 5-bromo-4-chloro-3-indolyl
phosphate/nitroblue tetrazolium (BCIP/NBT) as the active
chromogen. Using this procedure, the anti-NF68 mono-
clonallabels a single band having an apparent M, of 68 kDa,
and the NF200 monoclonal produces a somewhat smeared
band having an apparent M, of 2200 kDa. The smearing of
NF200 is caused by the physiochemical properties of this
long, rigid protein and its extensive, variable level of phos-
phorylation (Julien and Mushynski, 1982; Nixon and
Sihang, 1991).
4. Statistical Analysis
The studies described were performed with 6-8 rats. Each
sample was performed in duplicate for a total of 12-16 data
points per condition. Quantitative analysis of the proteins
employed a computer-assisted, linear scanning densitometer
(GS300, Hoefer Scientific). All quantitative readings were
performed within a linear range of optical densities. All
lanes on immunoblots were scanned in the dark under
optimal conditions three times, and the results were aver-
aged for inclusion in data analysis. Lanes that contained
prominent gel artifacts were excluded from further data
analysis.
Statistical significance of NF immunoreactivities was
evaluated using an independentt-test analysis of the pooled
data and a post-hoc Tukey-Honest significant difference
(HSD)analysis of variance (ANOVA) to detect percentage
differences by group analysis for all gels analyzed. All
values were expressed as percent change relative to naive
values on each immunoblot. Data were considered signifi-
cant if p<0.05.
B. RESULTS
1. Sham Injury Does Not Affect NF68 and NF200 Levels
NF68 and NF200 protein levels from sham-injured ani-
malsat all time points were compared with levels from naive
rats to determine the effect of animal surgery (craniotomies)
in the absence of TBI. Both hippocampaland cortical tissues
were examined, ipsilaterally and contralaterally. NF68 and
NF200 levels from naive cortex did not differ significantly
from cortices of sham-injured animals at any post-injury
time investigated (p<0.05). Similarly, NF68 and NF200 also
were unchanged in sham-injured hippocampal tissue when
compared with naive hippocampi (p<0.05) (Table 2). Hence,
sham injury had no significant influence on NF68 or NF200
protein levels in either the cortex or the hippocampus at any
time point investigated.
Theeffect of lateral cortical impact injury on the levels of
axonal cytoskeletal proteins was examined in adult rats. TB1
caused a significant decrease in the protein levels of two
major neurofilament (NF) proteins, NF68 and NF200. By
quantitating immunoreactivity measurements of Western,
blots NF68 and NF200 levels were determined in homoge-
nates of hippocampal and cortical tissue taken at several
intervals post-injury. Sham injury had no effect on NF
protein levels. However, injury was associated with a sig-
nificant (up to 41.8%) loss of NF68,restricted to the cortex
ipsilateral to the injury site. NF68 loss was detectable as
early as three hours and as late as two weekspost-injury.
Similarly, TBl induced a decrease in NF200 protein,
although losses were observed both ipsilateral (71.7%) and
contralateral (66.9%) to the injury site. No loss of NF68 or
NF200 protein was detected in hippocampal samples
obtained from the same injured animals. An increase in the
presence of lower molecular weight NF68 immunopositive














injured ipsilateral cortex. This NF68 antigenicity pattern
suggests the production of NF68 breakdown products
(BDPs) caused by the pathological activation of neuronal
proteases such as calpain.
Putative NF68 BDPsincreased significantly until one day
post-injury, suggesting that NF degradation may be ongoing
and indicating that a potential therapeutic window may exist
within the first 24 hrs post-injury. In summary, these data
identify specific biochemical alterations of the axonal
cytoskeleton following TBI.
EXAMPLE12
EXTRACELLULAR CHOLINE LEVELS AND
[7H]-CHOLINE UPTAKE IN HIPPOCAMPUS2-
WEEKS AFTER CORTICAL IMPACT INJURY IN
RATS
Chronic spatial memory deficits following experimental
traumatic brain injury maybe,in part, attributable to deficits
in central cholinergic neurotransmission. These studies
examinedthe rate-limiting factor in acetylcholine synthesis;
availability and neuronal uptake of its precursor, choline. In
the first study microdialysis was used to measure extracel-
lular choline levels within the dorsal hippocampus at
2-weeks post-injury, an interval associated with spatial
memory deficits. Ten rats were injured by lateral cortical
impact. Ten additional rats served as sham controls. Under
anesthesia, a microdialysis probe (3 mm tip) was placed into
their dorsal hippocampusand perfused withartificial cerebro
spinal fluid CSF. Samples were collected for 20 minutes
(min) and measured by HPLC. The data showed no differ-
ence in basal choline levels between injured (3.86+0.53
pmol/20 min) and sham (3.35+0.50) rats.
In a second study high-affinity [*H]-choline uptake was
measured in a synaptosomal preparation of hippocampal
tissue removed from 11 injured and 12 sham rats 2-weeks
following TBI. Significant differences were found in the
maximum velocity of choline uptake (Vmax) between
injured (46.2+2.3 pmol/mg/5 min) and sham (58.8+2.1) rats,
while no differences in affinity constants (K,,) were found.
The results suggest that post-traumatic cholinergic deficits
are notattributable to decreased availability of choline, but
may be associated with either a decreased ability of cholin-
ergic neurons to take up choline, or a loss of cholinergic
neurons.
EXAMPLE13
VISUALIZATION OF ACUTE STRUCTURAL
DERANGEMENTS OF CORTICAL NEURONS
IN THE RAT FOLLOWING TBI USING NF
IMMUNOFLUORESCENCE
Quantitative Western blot studies demonstrated signifi-
cant losses of neurofilament 68 (NF68) and neurofilament
200 (NF200), as well as the presence of low molecular
weight proteolytic fragments as early as 3 hours and for as
long as two weeks followinglateral cortical impact injury in
rats. Three hours following injury, NF68 decreased 23% and
NF200 decreased 50% in the ipsilateral cortex. In the
contralateral cortex, TBI produced significant loss (65%) of
only NF200 3 hours after injury. Consequently, NF immu-
nofluorescence was used to study the morphological corre-
lates of early NF protein decreases observed 3 hrs post TBI.
Using anti-NF200 (Sigma N52) and anti-NF68 (Sigma
NR4) antibodies that recognize their appropriate subunits
independent of phosphorylation state, total NF protein was
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detected regardless of post-translational modifications. Sec-
ondary anti-mouse IgG was conjugated with either FITC or
Rhodamine. TBI induced differential alterations in NF68
and NF200 immunolabeling which were restricted to the
ipsilateral contusion site (24 mm lateral from the middle
longitudinal tissue [MLF[) as well as a focal contralateral
contusion site (1-2 mm from MLF).
NF200 immunofluorescence revealed a prominent frag-
mented appearance of the apical dendrites within pyramidal
neuronal layers 3 and 5, as well as a loss of fine dendritic
arborization within layer 1. NF68 immunofluorescence
detected subtle and less severe ultrastructural changes such
as focal vacuolization along apical dendrites, although mac-
rostructural changes (i.e., broken apical dendrites) also
occurred to a lesser degree. Although axonal alternations
were observed with anti-NF68 and anti-NF200 in the corpus
callosum and other white matter areas, axonal alterations
were markedly less than the acute NF immunofluorescence
changes seen in dendritic regions.
Collectively, these observations suggest that early NF
protein loss is observed in dendrites, and to a lesser extent,
in axons following injury. Since neurofilaments are struc-
tural proteins found abundantly in dendritic as well as
axonal processes, diffuse injury to neuronal processes may
be an important morphological feature of TBI. Immunohis-
tochemical studies were employed to exam the temporal and
regional characteristics of this diffuse process injury (DPI).
EXAMPLE14
AMYLOID PROTEIN PRECURSOR LEVELS
ARE ALTERED IN RAT HIPPOCAMPUS AND
CORTEX FOLLOWING TRAUMATIC BRAIN
INJURY
Increasesin the diffuse deposition ofAS protein can occur
following traumatic brain injury in humans. Furthermore,
levels of the precursor to AS protein (amyloid protein
precursor: APP)are increased in rodentbrain following CNS
lesion. In order to investigate the effect of traumatic brain
injury on APP levels, homogenates of rat cortex and hip-
pocampus were prepared 3 h, 1 day, 7 days, or 14 days after
lateral cortical impact injury. SDS-PAGE Western blots were
immunostained using an antibody which recognizesall three
main forms of the amyloid protein precursor (22C11,
Boehringer-Mannheim,Indianapolis, Ind.). 2-D densitomet-
ric scanning was used to quantify changes in protein levels.
Data indicated that APP levels were significantly
decreased at 2 weeks in cortex ipsilateral to injury. In
contrast, a significant increase was observed in ipsilateral
hippocampus 1 day after injury. These results indicate that
alterations in APP after traumatic brain injury are regionally
specific. Thus, mechanisms mediating TBl]-induced changes
in APP levels may differ in various regions of the rodent
brain.
EXAMPLE15
EFFECTS OF LATERAL CORTICAL IMPACT
INJURY ON AXONAL PROTEINS
Theeffect of lateral cortical impact injury on the levels of
axonal cytoskeletal proteins has been examinedin adultrats.
Traumatic brain injury (TBI) causes asignificant decrease in
the protein levels of two prominent neurofilament (NF)
proteins, NF68 and NF200. Quantiative immunoreactivity
measurements were performed using Western blots to exam-














and cortical tissue taken at several intervals post-injury.
Sham injury had no effect on NF protein levels. However,
injury was associated with a significant loss of NF68,
restricted to the cortex ipsilateral to the injurysite.
1. Injury Results in Significant loss of NF68 and NF200
NF68loss was detectable as early as 3 h andlasted at least
2 weeks post-injury. Similarly, TBI induced a decrease in
NF200 protein, although losses were observed both ipsilat-
eral and contralateral to the injury site. No loss of NF68 or
NF200 protein was detected in hippocampal samples
obtained from the same injured animals. An increase in the
presence of lower molecular weight (MW) NF68 immu-
nopositive bands was associated with the decrease of NF68
in the ipsilateral cortex. This NF68 antigenicity pattern
suggests the production of NF68 breakdown products
caused by the pathologic activation of neuronal proteases,
such as calpain. Putative NF68 breakdownproducts increase
significantly until 1 day post-injury, suggesting that NF
degradation may be ongoing until that time and indicating
that a potential therapeutic window mayexist within the first
24 h post-injury.
2. TBI Decreases NF68 Levels Only in Ipsilateral Cortex
The effect of lateral cortical impact injury on NF68
immunoreactivity in cortical tissue was examined at several
intervals post-injury. Naive, sham-injured, and cortical
impact-injured samples were examined for NF68 protein
content by SDS-PAGEand quantitative Western immunore-
activity at 3 h, 1 day, 7 days, and 14 days after injury.
Proteins were visualized on nitrocellulose transfers using an
anti-NF68 monoclonal antibody. A significant decrease in
NF68 protein was notedat all postinjury time points exam-
ined. The decrease in NF68 antigenicity was accompanied
by the appearance of two lower MW immunopositive bands
at 56 and 52 kDa.
In the contralateral cortex, no significant change in NF68
levels was noted between sham and injured samples. The
most prominentloss (58.2% of sham controls) occurred at 7
days post-injury. The process of NF68 loss was induced
within 3 h post-injury, but continued reduction of NF68
occurred beyond 1 week.In addition, NF68 levels at 1 day
(63.9% of sham controls) were significantly lower than the
3 h value (78.9% of sham controls) (p<0.04). Post-hoc
Tukey-HSD ANOVAanalysis (% difference group) for all
gels at p<0.05 also showed significance at all time points
except 3 h. In addition to labeling of the prominent 68 kDa
band, additional immunopositive bands were found in
samples from injured cortex. These lower MW immunopo-
sitive bands appeared prominently at 56 kDa and 52 kDa and
are accompanied by other minorstaining bands in the same
MWrange (FIG. 9A and FIG. 9B)
TABLE 2
 
NF68 AND NF200 LEVELS IN HIPPOCAMPAL SAMPLES*
3h 1 Day 7 Days 14 Days
NF68 Protein Levels
Ipsilateral
Sham 99.9 + 6.6 94.6 + 1.6 918233 931245
Injured 88.9 + 5.9 86.8 + 4.8 85.7+£2.0 84.5 + 3.0
Contralateral
Sham 101.9 + 5.3 97.2241 95.1+7.6 944+ 3.6





NF68 AND NF200 LEVELS IN HIPPOCAMPAL SAMPLES*
3h 1 Day 7 Days 14 Days
NF200 Protein Levels
Ipsilateral
Sham 94.1 + 6.1 96.6+18.0 1031+15.2 87.8+11.5
Injured 83.9 +10.4 110.9 +5.5 87.8+411.5 87.2+7.8
Contralateral
Sham 94.2 + 8.3 96.4 + 1.6 96.9 + 1.6 78.9 + 9.4
Injured 105.4 + 6.4 95.6 + 10.3 87.7+11.6 86.6 +£4.2
 
*NF68 and NF200 levels in hippocampus after severe cortical impact TBI.
The effect of lateral cortical impact injury on NF68 and NF200 immunore-
activity in hippocampal tissue was examined at several intervals post-
injury. Naive, sham-injured, and cortical impact-injured samples were
examined for neurofilament protein content by SDS-PAGEand quantita-
tive Western immunoreactivity at 3 h, 1 day, 7 days, and 14 days after
injury. Proteins were visualized on nitrocellulose transfersusing appropriate
monoclonal antibodies. Immunoblots were analyzed quantitatively by
computer-assisted scanning densitometry. Data are expressed as percentage
relative to naive controls. No significant changes in NF68 or NF200 pro-
tein levels are detected in hippocampaltissue either ipsilateral or contralat-
eral to the injury site. Statistical analysis of the data included an indepen-
dentt-test of the pooled data and a post hoc Tukey-HSD ANOVAto detect
percentage difference by group analysis for all gels analyzed. All values
were p < .05. Thus, no injured groups showed significant differences from
the sham-injured controls.
Cortical impact injury was associated with the onset of a
pronounced and prolonged loss of NF68 in the ipsilateral
cortex. NF68 levels in the ipsilateral cortex were signifi-
cantly reduced at 3 h, 1 day, 7 days, and 14 days. NF68
levels in the contralateral cortex did not differ from sham
controls at any time point studied. No prominent lower MW
immunopositive bands were seen in the contralateral cortical
samples. Thus, the data suggest a clear differential reduction
in NF68 protein selective to the ipsilateral cortex caused by
TBI.
3. TBI Decreases NF200 in Cortical Tissue
The effect of lateral cortical impact injury on NF200
immunoreactivity in cortical tissue was also examined at
several intervals post-inyjury. Naive, sham-injured, and cor-
tical impact-injured samples were examined for NF200
protein content as described at 3 h, 1 day, 7 days, and 14 days
after injury. Proteins were visualized on nitro-cellulose
transfers using an anti-NF200 monoclonal antibody. In the
ipsilateral cortex, a significant decrease in NF200 protein
was noted at all post-injury time points examined. In the
contralateral cortex, a reduction of NF200 levels was noted
between sham and injured samples at all intervals post-
injury.
TBI also caused a dramatic reduction in cortical NF200
protein levels. NF200 loss was most prominent in the
ipsilateral cortex, but unlike the NF68 changes, significant
loss of NF20 occurred in the contralateral cortex as well. In
the ipsilateral cortex, NF200 loss was seen at 3 h and
remained significantly reduced as long as 2 weeks post-
injury. The greatest loss (28.3% of sham control) was
observed at 7 days post-injury.
NF200 immunoreactivity in the contralateral cortex also
showed a consistent TBI-induced reduction. Although each
time point analyzed showed reduction of NF200 levels
relative to sham controls, significant decreases occurred
only at 3 h and 14 days. The increased variability of NF200
sampling suggests a more diverse insult to NF protein
contralaterally.

















NF68 and NF200 immunoreactivity was performed on the
corresponding underlying hippocampaltissuefor all animals
studied. NF68 immunoreactivity in the ipsilateral and con-
tralateral hemispheres did not show any significant
differences, (p<0.05) compared with sham-injured controls.
Similarly, NF200 demonstrated no significant loss in either
hemisphere of injured animals compared with sham-injured
animals (Table 2). The low MW NF68 immunopositive
bands were not seen in hippocampal samples.
5. Post-TBI NF Protein Loss Is Associated with the Presence
of NF Breakdown Products
Immunoanalysis of NF68 on Western blots demonstrated
a prominent single band at 68 kDa in naive, sham, and
injured animals. In injured samples, however, the decrease
in NF68 levels was associated with the appearance of lower
MW immunopositive bands (FIG. 9A and FIG. 9B). The
minor bands were found at molecular weights of 56 kDa and
52 kDa. The presence of the lower MW bandsassociated
with TBI and the concomitant reduction of NF68 suggest the
appearance of lower MW breakdown products (BDPs)
caused by the post-injury activation of proteases. The low
MW immunopositive proteins appeared at 3 h post-injury
and attained their highest levels at 1 day (FIG. 9B). These
bands were markedly reduced in 7 and 14 days samples. The
presence of low MW immunopositive bands has been
reported previously following both in vitro and in vivo
proteolysis of NF68 (Schlaepferet al., 1984; Schalepfer and
Zimmerman, 1985).
6. The Role of Cytoskeletal Proteins in Trauma
Studies have addressed the relationships between changes
in axonal and dendritic cytoskeletal proteins and the mor-
phopathologic outcome of trauma. These quantitative analy-
ses indicate that NF changes precede neuronal cell death
and, further, may not be exclusively associated with cell
death. For example, cortical NF68 levels were significantly
decreased at 3 h post-injury, well in advance of cellular
necrosis in the cortex. In addition, cortical NF200 loss
occurred contralateral to the impact site, in the absence of
substantial cell death.
Similarly, loss of cortical NF200 has been reported con-
tralaterally to middle cerebral artery occlusion in rats where
no cell death occurred but which may contribute to postis-
chemic symptomatology (Inuzukaet al., 1990b). Subsequent
studies directly linked to neuropathology may determine
whether the NF losses reported are initial components of
axonal damage and separation or are the beginnings of
Wallerian degeneration of the distal axonal segment of the
already severed axon. Alternatively, decreases in NF may
represent persistent sublethal alteration in the cytoskeleton
not associated with classic morphopathologic features of
traumatic axonal injury.
Even in the absenceof cell death or axonal disruption, the
NF changes identified may have important consequences
that compromise neuronal function and may contribute to
sublethal neuronal injury. NF68 and NF200 are key elements
of neurofilaments, and extensive loss of these proteins after
TBI may compromise neurofilament function in injured
neurons. Such insults may becritical to neuronal viability
and normal function because neurofilaments appear to play
a crucial role in the maintenance of axonal and dendritic
structure, caliber, axoplasmic transport, and other functions
(Hoffman and Lasek, 1975; Mellgren and Murachi, 1990;
Oliver et al. 1989). These actions may be significantly
impaired post-injury with the losses of NF protein reported
here.
NF68lossat 1 day post-injury is significantly greater than
the loss observed at 3 h post-injury. This difference could
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indicate that the pathologic processes causing NFloss are
incomplete 3 h post-injury and are ongoing at that time.
Because the NF loss at 1, 7, and 14 daysis not statistically
different, the pathologic causes of NF loss may have peaked
at these times. These observations are consistent with the
appearance of NF68 BDPs, which also peak 1 day post-
injury. In experimental models of ischemia, administration
of anti-calpain compounds has proven effective in prevent-
ing ischemia-induced cytoskeletal protein loss (Inuzuka et
al., 1990a; Lee et al., 1991; Simanet al., 1989). In models
of TBI, treatment with moderate hypothermia reduces
injury-associated MAP2 loss (Taft et al., 1993). Thus, the
changes in NFprotein levels may be amenableto therapeutic
intervention in the first 24 h post-TBI. The time course of NF
changes further suggest that NF loss will not recover to
normal (sham control) levels within the first 2 weeks fol-
lowing insult. The examination of longer post-injury inter-
vals may be necessary to determine whether neurons can
independently recover NF protein levels following severe
cortical impact TBI.
7. Conclusions
Several important conclusions were derived from these
studies. First, the pattern and temporal progression of NF68
and NF200 loss were similar. Reductions in NF levels were
observed within 3 h post-injury and appear unresolved 2
weeks later. Second, the extent of NF protein loss was
greater in the hemisphere ipsilateral to the injury site com-
pared with the contralateral side. For example, a pronounced
loss of NF68 wasseen ipsilaterally, but no loss was observed
contralaterally. Third, the loss of NF200 was more extensive
compared with loss of NF68.In the ipsilateral cortex, NF200
loss reached 70% (30% of sham control values), whereas
NF68 loss was 40% (60% of sham control values). Fourth,
a higher degree of sample-to-sample variability was
observed with NF200 compared with NF68. A potential
cause for the greater loss and higher variability of NF200
post-TBI may be NF200 subunit disassembly from the core
filament, thus increasing its availability for phosphorylation
or proteolysis or both. Further, because NF phosphorylation
state influences NF proteolysis by calpain (Pant, 1988),
variable levels of NF200 phosphorylation from animal to
animal may contribute significantly to the variability of
NF200 antigenicity.
EXAMPLE16
RESCUE OF NEUROFILAMENT LOSS FROM
NEURONAL INJURY BY BDNF GENE
TRANSFECTION IN PRIMARY SEPTO-
HIPPOCAMPAL CELL CULTURE
Cortical impact injury in rats can produce significant loss
of neurofilament proteins including medium, low and high
molecular weight neurofilament proteins (NF-L, NF-M,
NF-H). In addition, brief depolarization of primary septo-
hippocampal cell cultures can also produce significant losses
of neurofilament proteins. Recent studies indicate that
BDNFincreases neurofilaments in hippocampal cell cul-
tures (Yip et al., 1993) and increases survival of cortical
neurons (Ghoshet al., 1994). Using a liposomal mediated
system for transfecting cDNA of neurotrophins into central
nervous system cells primary septo-hippocampal cell cul-
tures were transfected to determine the therapeutic potential
of BDNFgene transfection in facilitating the recovery of
neurofilament loss caused by depolarization injury.
Employing a pUC19 based plasmid, rat BDNF cDNAwas
subcloned into a unique NotI site under the control of the














somes and transfected into primary septo-hippocampalcell
cultures one day after depolarization injury (6.0 min depo-
larization with 60 mM KCIandthe presence of 2.8 mM
Ca**) (FIG. 11A and FIG. 11B). Three days after depolar-
ization injury, Western blot and immunohistochemical
analyses detected significant loss (42% of NF-M and NF-H
proteins (Sternberger SMI31 antibody) in untreated cultures
(FIG. 13A and FIG. 13B). However, densitometric scanning
of Western blot data indicated that BDNF transfection
produced a two-fold increase in NF-M/NF-H three days
following injury as compared to untreated cultures. Immu-
nohistochemical studies also detected enhanced NF-M/
NF-H immunolabeling in injured neurons following BDNF
transfection as compared to untransfected, injured controls.
Thus, BDNF genetransfection may be useful as a therapeu-
tic tool for blunting neurofilament loss associated with
injury to central nervous system neurons.
EXAMPLE17
BDNF TRANSFECTION RESCUES NEF IN
INJURED ANIMALS
To demonstrate the effects of TBI on levels of neurofila-
ment protein in vivo, NF-H levels were determined in
animals following TBI using SDS-PAGE and Western
analysis. FIG. 13A showsthe decrease in NF-H levels which
occur as a result of TBI. Tissue was dissected from the
parietal cortex ipsilateral to the site of cortical impact. Two
days following cortical impact injury, a substantial loss of
NF-H protein was detected in the injured(I) rat compared to
the non-injured (N) control. Densitometric scans of the two
samples indicated a 38% decrease in NF-H levels following
cortical impact injury. (In arbitrary units, 4083 density units
were recorded for the non-injured NF level, and 2614
density units were recorded for the injured NF level).
To demonstrate the successful rescue of NF-H levels in
vivo after the liposome-cDNAtransfection methods of the
present invention, neurofilament recovery was determined
by following the immunoreactivity of NF-H using SDS-
PAGEand Western analysis. Tissue was dissected from the
parietal cortex ipsilateral to the site of cortical impact as in
FIG. 13A. Compared to the control animal (C) which
received liposomes alone, the animal transfected with the
liposome-BDNF cDNAcomplex (1:3) ratio) (B) showed a
significant restoration of NF-H protein two daysafter injury.
In both cases, injections were made into the ventricle
ipsilateral to the injury site immediately after injury. An 8%
increase in NF-H was detected 2-days post-trauma in the
BDNF-transfected animal. (By densitometric scans, arbi-
trary units of 5516 and 5862 density units were recorded for





B-Gal activity is visualized in vivo by histochemical
staining using 5-bromo-4-chloro-3-indolyl-B-D-
galactopyranoside (X-Gal). Culture wells are washed with
phosphate-buffered saline (PBS) and fixed with 0.5 ml
containing 2% (v/v) paraformaldehyde and 0.2% glutaral-
dehyde in H,O for 5 min at 4° C.Cells are rinsed again with
PBSand then stained with 0.5 ml per well of the following
solution: 7 mM Na,HPO,, 23 mM NaH.PO,, 1.3 mM
MgCl, 3 mM K3Fe(CN),, 3mM K,Fe(CN), and 1 mg/ml
X-Gal (diluted from a 40 mg/ml stock solution in
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dimethylformamide). Cells expressing B-Gal are stained
blue after incubation at room temperature overnight.
2. mRNAAssessments
Cells grown in culture are lysed by adding 0.2 ml of
RNAzol B (Cinna/Biotec Laboratories, Inc.) per 10° cells.
The RNAis solubilized by passing the lysate several times
through a pipette. After adding 0.2 ml chloroform per 2 ml,
the homogenate is incubated at 4° C. for 15 min, and the
aqueous phase containing the RNAis transferred to a fresh
tube. The supernatant is removed after centrifugation (12,
000xg) for 15 min at 4° C. RNA pellets are washed with
75% ethanol, dried briefly and re-suspended in RNase-free
water.
For in vivo studies, hippocampal tissue around injection
sites and/orother loci is dissected at 4° C. and homogenized
with RNAzol B (2 ml/100 mg) by a motorized Teflon™
pestle homogenizer (10 up-and-down stokes). Methods are
then similar to those employed for in vitro studies.
3. Reverse Transcription-Polymerase Chain Reaction (RT-
PCR™)
Reverse transcription is performed using oligo (dt) as
primers and M-MLVreverse transcriptase (Perkin-Elmer,
Norwalk, Conn.). Twenty yg of total RNAfrom each sample
is used for cDNA synthesis. The reaction is carried out at 42°
C. for 2 hours using 20 units of recombinant reverse
transcriptase devoid of phenol, then with chloroform, fol-
lowedbyprecipitation with ethanol. The cDNA isdissolved
in 50 wl of TE buffer.
For PCR™,two pairs of forward and reverse primers for
BDNF and NGFare used. The sequence of the BDNF/5
primer is 5'-GCAAACATGTCTATGAGGGT-3' (SEQ ID
NO:1) and BDNF/3 is 5'-GGTCAGTGTACATACACAGG-
3' (SEQ ID NO:2); the sequence NGF/5 primer is
5'-GGCATGCTGGACCCAAGCTC-3' (SEQ ID NO:3) and
NGF/3 is 5'*GCGCTTGCTCCGGTGAGTCC-3' (SEQ ID
NO:4) (Giordanoet al., 1992). 2 ul cDNA and 40 pmolof
primer are used for PCR™. PCR™ is carried out in a
programmable heating block (Perkin-Elmer) using cycles
consisting of denaturation at 95° C. for 1 min, followed by
annealing at 55° C. for 1 min and cDNA extensionat 72° for
2 min.
After amplification, the samples electrophoresed on 1.5%
agarose gel. The gels are stained with ethidium bromide and
photographed under UV light. The intensity of PCR™
product bandsare quantitated by a computer-assisted, linear-
scanning densitometer in reflectance mode (Hoefer Scien-
tific Instruments, San Francisco, Calif.).
Since previous studies indicated that B-actin mRNA did
not changein the inventors’ injury model (Yanget al., 1993),
B-actin mRNAis utilized in the same RNApreparation as
one internal control for RT-PCR. The sequence for the
forward primer is 5'-CCTTCCTGGGCATGGAGTCCTG-3'
(SEQ ID NO:5). The sequence of the reverse primer is
5-GGAGCAATGATCTTGATCTTC-3' (SEQ ID NO:6). To
check for the possibility of DNAcontamination during RNA
preparation, the same RNA samples are included without
performingthe reverse transcription procedure. This control
RNApreparation undergoes the same PCR™ process with
the sample from the RT product.
4. In Situ Hybridization
Cells are treated with 0.25% trypsin for 5 min at 37° C.
The cell suspensionsare transferred to poly-L-lysine-coated
slides which are fixed with 4% paraformaldehyde for 20
min. After washing with PBS, the slides are dried with
increasing gradients of ethanol and store at -80° C. for
future in situ hybridization. Rats are perfused intracardially














fixative A (0.8 g NaOH, 8 g paraformaldehyde, 1.64 g
sodium acetate in 200 ml distilled H,O, pH 6.5) at 20
ml/min, followed by fixative B (1.4 g NaOH, 14 g
paraformaldehyde, 13.35 g borax, pH 9.5). Brainsare cryo-
protected in 10% sucrose-fixative overnight at 4° C. Coronal
sections (15) are prepared and mount on subbed poly-L-
lysine-coated slides and store at -80° C. for in situ hybrid-
ization.
Slides are dried overnight and subjected to 0.001% pro-
teinase K digestion at 37° C. for 20 min, then immersed in
0.1 M triethanolamine (TEA) with 0.25% acid anhydride for
10 min. Subsequent dehydration is carried out sequentially
in 50, 70, 95 and 100% ethanol (3 min each). The hybrid-
ization is performed with a *°P-labeled cRNA probe (107
cpm/ml) overnight at 55° C. The cRNA probe is obtained
from the cDNA clone in pKS vector using T7 or T3 RNA
polymerase (Simmonset al., 1989). After hybridization, the
slides are washed sequentially in 2x, 1x, 0.2x, 0.1xSSCat
43° C. and dehydrated in 50%, 70%, 95%, and 100% ethanol
(3 min each). Brain slides are exposed to Kodak (Rochester,
N.Y.) XAR-5 film overnight. After film development, the
slides are processed by emulsion autoradiography. After
emulsion film development, slides are counterstained with
hematoxylin. After dehydration and mounting, slides are
examined by dark-field microscopy.
Importantly, the inventors have subjected in situ hybrid-
ization slides to DNAse treatment to exclude possible
hybridization between the antisense probe and the plasmid
cDNAconstruct.
5. Protein Assay
Proteins are determined using antibodies for NGF,
pyseeF®, pi40’™, p145°" (Hutton et al., 1992), and a
monoclonal antibody (clone 27/21) specific for rat and
mouse 6 (2.5S) NGFthat is also suitable for ELISA deter-
minations if NGF proteins in brain tissue. Receptor anti-
bodies are made to synthetic peptide segments on the
different neurotrophin receptors and allow determination of
different trks as well as differential staining of full and
truncated versions of the different trks.
6. Immunohistochemistry
Cells are fixed in tissue culture wells by the gentle 1:1
addition of 8% paraformaldehyde in 0.12 M PBS(pH 7.3)
for 20 min. After brief wash with PBS,the cells are ready to
be immunostained. Rats are perfused intracardially with 120
mlof saline and 240 ml ofa fixative solution containing 4%
paraformaldehyde in 0.12 M phosphate buffered saline
(PBS) (pH 7.3). Rat brains are removed and post fixed
overnight at 4° C. in 4% paraformaldehyde in 0.12 M
phosphate buffer. Coronal sections (154) are prepared and
mount on subbed poly-L-lysine coated slides.
Cultures are washed with PBS buffer and incubated in
normal goat serum (4%) for one hour. Following 3 5-min
washes with PBS, the cultures are incubated with Goat
anti-Mouse IgG (Chemicon International, Inc., Temecula,
Calif.) antibodies (dilution 1:100) for two hours at room
temperature. The cultures are quenched for endogenous
peroxidase with 0.03% of H,O, in methanol for 30 min at
room temperature. After 35-min washes with PBS, the
cultures are incubated with Avidin-Peroxidase solution
(Vector Lab, Burlingame, Calif.) for one hour at room
temperature. Following 35-min washes with PBS,cultures
are pre-incubated with diaminobenzidine tetrahydrochloride
(DAB) (Vector Lab) and 0.006% H,O, for 10 min.
Cultures are washed with distilled water and counter-
stained with hematoxylin. After dehydration and mounting,
cultures are studied by light microscopy on an inverted
(tissue culture) microscope. Similar procedures are used for
6,096,716
41
p75*OF®, p140"™ and p145””" receptor immunohistochem-
istry (Turner and Perez-Polo, 1993). For immunostaining of
brain slices, coronal sections are mounted on slides and the
same protocol is followed except that rinses are 5 times for
5-min each to minimize backgroundstaining.
7. ELISA
For in vitro studies, cells are treated with lysis buffer and
extracted on ice for 10 min. The extractions are centrifuged
at 20,000xg for 15 min at 4° C. The supernatant is assayed
for protein using the Bradford method with a BSA standard
(Ausubelet al., 1993). The samples are aliquoted and stored
at -80° C. for later ELISA.Forin vivo studies, tissue from
the hippocampusandother brain regions are dissected at 4°
C. and homogenized in ice-cold buffer (50 mM Tris; 2 mM
EDTA; 2 mM DTT; 100 uM leupeptin; pH7.5) by a motor-
ized Teflon pestle homogenizer (10 up-and-downstrokes).
The homogenates are then processed as described above for
later ELISA.
8. Antibody-Sandwich ELISA
Specific anti-NGF or anti-BDNEFantibodies are diluted to
a final concentration of 0.2 to 10 yg/ml. The optimal
concentrations of anti-NGFor anti-BDNFantibodies and the
conjugate necessary to detect the sample NGF or BDNFare
determinedbycriss-cross serial dilution analysis. After final
concentrations of anti-NGF or anti-BDNF antibodies are
determined, wells of a plate are coated with serial concen-
trations of anti-NGF or anti-BDNFantibodies. The standard
NGF and BDNFdilution series are prepared by 1:3 dilution
of stock NGF and BDNFsolutions.
After tissue homogenization, sample homogenates are
diluted in blocking buffer. 50 wl aliquots of the diluted
homogenate and standard NGF and BDNFdilutions are
added to the antibody-coated wells and incubated two hours
at room temperature. After washing the plate with water and
blocking buffer, a 50 ul antibody-alkaline phosphatase con-
jugate is added to each well and incubated for two hours at
room temperature. After another wash with water and block-
ing buffer, 75 “l of NPP substrate solution is added to each
well followed by incubation for 1 hour at room temperature.
After color development, the plate is read on a microtiter
plate reader. The NGF and BDNFconcentrations are deter-
mined from a standard concentration curve.
9. Biological Assay of Neurotrophin Activity
Biological assays for NGF induced differentiation are
performed by assay of NGF activity in conditioned media,
cells or tissues. Assays employ both the rat pheochromocy-
toma (PC12) cell line (Greene and Tischler, 1976) and
nodose and dorsal root ganglia explants (Lindsay and
Rohrer, 1985). The assays score neurite outgrowth and
differentiation as seen in increased length and complexity of
neurites. Assays employ standardization of neurotrophic
dose-response curves as well as confirmation of blockade by
appropriate antisera. PC12 cells are photographed and
evaluated for morphological differentiation five days after
treatment with appropriate experimental media. Nodose and
dorsal root ganglia explants from embryonic day 8 are
overlaid with the experimental media. 24-48 hourslater, the
ganglia are photographed and scored for neurite outgrowth
(Perez-Polo, 1987).
10. Calculation of Transfection Efficiency
Transformation efficiency in B-Gal transfected cells is
calculated after X-Gal staining and hematoxylin counter-
staining by determining the total cell number and the num-
ber of 6-Gal positive cells in at least 3 randomly chosen
non-overlappingfields per well. Transformation efficiency is
expressed as a percentage of B-Gal positive cells to total














procedures that measure enzymeactivity of the total popu-
lation of transfectedcells (e.g., luciferase-transfection quan-
titation assays) rather than enzymeactivity within individual
cells which can be visualized and counted.
Transformation efficiency in NGF-and BDNF-transfected
cells will first be estimated using quantitative RT-PCR™.
Studies have shownthat such a qualitative comparison was
sufficient for determining the relative optimal transforma-
tion efficiency when several cDNA:liposomes ratios are
compared. In order to determine the precise transfection
efficiency of an optimal ratio, in situ hybridization was
combined with hematoxylin counterstaining to determine
the total cell number and the numberof successfully trans-
fected cells (cells expressing NGF and BDNF mRNAat
greater then background levels) in at least 3 randomly
chosen non-overlappingfields per well. Transformation effi-
ciency is expressed as a percentage of successfully trans-
fected cells to total cells.
Transfection efficiency for in vivo studies is calculated on
the basis of cell counts made in 2.0 mm? area units of
coronal tissue sections adjacent to the site of injection. The
total area sampled depends upon the extent of transfection
observed. As stated for in vitro studies, B-Gal transfection
efficiency studies employ X-Gal staining and hematoxylin
counterstaining to determine the total cell number and the
number of 6-Gal positive cells. In studies of NGF and
BDNF,in situ hybridization is combined with hematoxylin
counterstaining to determine the total number and the num-
ber of successfully transfected cells. Transformation effi-
ciency is expressed as a percentage of successfully trans-
fected cells to total cells.
11. Histopathological Assessment
In general, histological assessments are done in conjunc-
tion with in situ and immunohistochemical analyses. Hem-
orrhage and necrosis is detected by conventional hematoxy-
lin and eosin (H&E) staining. Edema formation
(extravasated blood plasma) is monitored by immunostain-
ing for plasma albumin, and then comparingthis pattern to
the hemorrhage in the adjacent serial H&E-stained section.
Viable neurons in brain grey matter are visualized by con-
ventional Nissel stain. Axonal injury is determined by
Palmgren’s silver impregnation method for the presence of
reactive axonal swellings (retraction balls).
Macrophagesare detected using commercially-available
monoclonal antibodies (ED1, ED2, ED3) specific for rat.
Astroglial reaction is determined using Glial fibrillary acidic
protein (GFAP) employing a mix of commercially-available
mouse monoclonal antibodies.
All of the compositions and methods disclosed and
claimed herein can be made and executed without undue
experimentation in light of the present disclosure. While the
compositions and methods of this invention have been
described in terms of preferred embodiments, it will be
apparent to those of skill in the art that variations may be
applied to the composition, methods andin the steps or in the
sequence of steps of the method described herein without
departing from the concept, spirit and scope of the invention.
More specifically, it will be apparent that certain agents
which are both chemically and physiologically related may
be substituted for the agents described herein while the same
or similar results would be achieved. All such similar
substitutes and modifications apparent to those skilled in the
art are deemed to be within the spirit, scope and concept of
the invention as defined by the appended claims.
REFERENCES
The following literature citations as well as those cited
above are incorporated in pertinent part by reference herein
for the reasons cited in the abovetext.
6,096,716
43
USS. Pat. No. 4,518,584.
USS. Pat. No. 5,168,050.
Adams et al., “Head injury in man and experimental
animals,” Acta Neurochir., 32:15-30, 1983.
Aldersonet al., “Brain derived neurotrophic factor increases
survival and differentiated functions of rat septal cholin-
ergic neurons,” Neuron, 5:297-306, 1990.
Arai et al., “A brief period of hypoxia causes proteolysis of
cytoskeletal proteins in hippocampalslices,” Brain Res.,
555:276-280, 1991.
Arai et al., “Calpain inhibitors improve the recovery of
synaptic transmission from hypoxia in hippocampal
slices,” Brain Res., 532:63-68, 1990.
Ausubel et al., “Current Protocols in Molecular Biology,”
Vol. 2., John Wiley and Sons, New York., 1993.
Balazsovits et al., “Analysis of the effect of liposome
encapsulation on the vesicant properties, acute and car-
diac toxicities, and antitumor efficacy of doxorubicin,”
Cancer Chemother. Pharmacol., 23:81-86, 1989.
Balentine, J. D., “Hypotheses in spinal cord traumaresearch,
In: Central Nervous System Status Report. D. Becker and
J. T. Povlishock (ed). National Institute of Neurological
Communicative Disorders and Stroke, National Institutes
of Health: Washington, D.C., pp. 455-461, 1985.
Banik etal., “Degradation of cytoskeletal proteins in experi-
mental spinal cord injury,” Neurochem. Res.,
7:1465-1475, 1992.
Barker and Murphy, “The NGF receptor—a multicompo-
nent system that mediates the actions of the neurotrophin
family of proteins,” Mol. Cell Biochem., 110:1-15, 1992.
Barinega, M., “Solving the delivery puzzle,” Science,
264:773, 1994.
Battlemanet al., “HSV1 vector-mediated gene transfer of the
human nerve growth factor receptor p75“defines
high-affinity NGF binding,” J. Neurosci., 13:941-951,
1993.
Beattie et al., “Experimental spinal cord injury: Strategies
for acute and chronic intervention based on anatomic,
physiological and behavioral studies, In: Pharmacologi-
calApproachesto the Treatment ofBrain and Spinal Cord
Injury. D. G. Stein and B. S. Sabel (eds). Plenum Press:
New York, pp. 43-74, 1988.
Bradford, M. M., “A rapid and sensitive method for the
quantification of microgram quantities ofprotein utilizing
the principle of protein-dye binding,” Anal. Biochem.,
72:238-259, 1976.
Breakefield and DeLuca, “Herpes simplex virus for gene
delivery to neurons,” New Biol., 3:203-218, 1991.
Brewer and Cotman, “Survival and growth of hippocampal
neuronsin defined medium at low density: Advantages of
a sandwich culture technique or low oxygen,” Brain Res.,
494:65-74, 1989.
Capecchi, M.R., “High efficiency transformation by direct
microinjection of DNAinto cultured mammalian cells,”
Cell, 22(2):479-488, 1980.
Caramia et al., “Experimental analysis of the mouse sub-
maxillary salivary gland in relationship to its nerve
growth factor content,” Endocrinology, 70:915-922,
1962.
Chan, P. H., “Antioxidant-dependent amelioration of brain
injury: Role of CuZn-superoxide dismutase,” J.
Neurotrauma, (suppl 2):S417-424, 1992.
Chang and Brenner, Focus, 6(4):66-69, 1988.
Chao et al., “Distinctive functions of NGF receptors,” J.
Neurochem., 61: $119, 1993.
Chin et al., “The proteolytic digestion of ox neurofilament















Clapp, D. W., “Somatic gene therapy into hematopoietic
cells: current status and future implication,” Clin.
Perinatol., 20:155-168, 1993.
Clintonet al., “Post-traumatic Alzheimer’s disease: prepon-
derance of a single plague type,” Neuropath. Appl.
Neurobiol., 17:69-74, 1991.
Coune, A., “Liposomes as drug delivery system in the
treatment of infectious diseases: Potential applications
and clinical experience,” Infection, 16:141-147, 1988.
Culver et al., “In vivo gene transfer with retroviral vector-
producer cells for treatment of experimental brain
tumors,” Science, 256:1550-1552, 1992.
Curiel et al., “Adenovirus enhancement of transferrin-
polylysine-mediated gene delivery,” Proc. Natl. Acad.
Sci. USA, 88:8850-8854, 1991.
Danos and Heard, “Recombinant retroviruses as tools for
gene transfer to somatic cells,” Bone Marrow Transplant,
9:131-138, 1992.
Dautingyet al., “The large neurofilament subunit (NF-H) of
the rat: cDNA cloning and in situ detection. Biochem.
Biophys. Res. Commun., 154:1099-1106, 1988.
Debs et al., “Regulation of gene expression in vivo by
liposome-mediated delivery of a purified transcription
factor,” J. Biol. Chem., 265(18):10189-10192, 1990.
Debset al., “Targeting of anti-Thy 1.1 monoclonal antibody
conjugated liposomes in Thy 1.1 mice after intravenous
administration,” Biochem. Biophys. Acta, 901:183-190,
1987.
Dellig and Seliger, “Genetransfer into brain tumorcell lines:
reporter gene expression using various cellular and viral
promoters,” J. Neurosci. Res., 26(3):390-396, 1990.
Dentonet al., “Production and characterization of neurotro-
phin antibodies for immunohistochemistry,” Soc. Neuro-
sci. Abstr., 19:255, 1993.
DeWitt et al., “Effects of traumatic brain injury on hippoc-
ampal physiology in vitro and cortical DC potentials in
vivo,” J CBF & Metab., 9(supp 1):S93, 1989.
Dixon et al., “A controlled cortical impact model of trau-
matic brain injury in the rat,” J. Neurosci. Methods,
39:253-262, 1991.
Dixon et al., “A fluid percussion model of experimental
brain injury in therat,” J. Neurosurg., 67:110-119, 1987.
Dixonet al., “Mechanisms of mild traumatic brain injury,”
J. Head Trauma Rehab., 8(3):21-32, 1993.
Dragunow and Robertson, “Generalized seizures induce
c-fos protein(s) in mammalian neurons,” Neurosci. Lett.,
82:157-161, 1987.
Drazba and Ralston, “Expression of E. coli B-galactosidase
in low density cultures of hippocampal neurons,” Lab of
Neurobiology, NINDS, NIH, Bethesda, Md. 20892, 1993.
Eglitis and Anderson,“Retroviral vectors for introduction of
genes into mammalian cells,” Biotechniques, 6:608-614,
1988.
Faller and Baltimore, “Liposome encapsulation of retrovirus
allows efficient superinfection of resistant cell lines,” J.
Virol., 49(1):269-272, 1984.
Fang et al., “Tissue-specific activity of heterologous viral
promoters in primary rat hepatocytes and Hep G2cells,”
Hepatology, 10:781-787, 1989.
Felgner et al., “Lipofection: A highly efficient, lipid-
mediated DNA-transfection procedure,” Proc. Natl. Acad.
Sci. USA, 84:7413-7417, 1987.
Finemanetal., “Concessive brain injury is associated with
a prolonged accumulation of calcium: a “°Ca autoradio-
graphic study,” Brain Res., 624:94-102, 1993.
Fischeret al., “Amelioration of cholinergic neuron atrophy
and spatial memory impairment in aged rats by nerve
growth factor,” Nature, 329:65-68, 1987.
6,096,716
45
Friedmann and Ginnah, “Gene therapy for disorders of the
nervous system,” Tibitech, 11:156-162, 1993.
Frommetal., “Expression of genes transferred into monocot
and dicot plant cells by electroporation,” Proc. Natl.
Acad. Sci. USA, 82:5824-5828, 1985.
Gage, et al., “Grafting genetically modified cells to the
brain, possibilities for the future,” Neuroscience
23:795-807, 1987.
Gelinas and Temin, “Nondefective spleen necrosis virus-
derived vectors define the upper size limit for packaging
reticuloendotheliosis viruses,” Proc. Natl Acad. Sci.
USA, 83:9211-9215, 1986.
Gennarelli et al., “Axonal injury in the optic nerve: A model
stimulating diffuse axonal injury in the brain,” J.
Neurosurg., 67:244-253, 1989.
Ghoshet al., Science 263:1618, 1994.
Giordanoet al., “Isolation of a population of transiently
transfected quiescent and senescent cells by magnetic
affinity cell sorting,” Exp. Cell Res., 992:993-997, 1991.
Girodanoet al., “Thyroid hormoneregulation of NGF, NT-3
and BDNF RNAin the adult rat brain,” Molecular Brain
Research, 16:239-245, 1992.
Gormanetal., “Analysis of acetylcholine release following
concussive brain injury in the rat,” J. Neurotrauma,
6:203-207, 1989.
Graham and Prevec, “Manipulation of adenovirus vectors,”
In: Murray, E. J., eds. Methods in Molecular Biology:
Gene Transfer and Expression Protocols, Clinton, N.J.:
The Human Press Inc., 109-128, 1991.
Graham and VanDerEb, “A new technique for the assay of
infectivity of human adenovirus 5 DNA,” Virology,
52:456-467, 1973.
Greene and Tischler, “Establishment of a noradrenergic
clonal line of rat adrenal pheochromocytomacells which
respond to NGF,” Proc. Natl. Acad. Sci. USA,
73:2424-2428, 1976.
Greene and Tischler, “PC12 pheochromocytoma cultures in
neurobiological research,” Adv. Cell Neurobiol., 373-414,
1982.
Hafti, F., “Nerve growth factor promotes survival of septal
cholinergic neurons after fimbrial transections,” J.
Neurosci, 8:2155-2162, 1986.
Hall et al., “Biochemistry and pharmacology of lipid anti-
oxidants in acute brain and spinal cord injury,” J.
Neurotrauma, (suppl 2):S425-442, 1992.
Hamm et al., “Cognitive deficits following traumatic brain
injury produced by controlled cortical impact,” J.
Neurotrauma, 9:11-20, 1992.
Hayes et al., “Neurotransmitter mediated mechanisms of
traumatic brain injury—acetylcholine and excitatory
amino acids; Central Nervous System Status Report:
1991,” J. Neurotrauma., 9: $173-S187, 1992.
Heath et al., “Liposome-mediate delivery of pteridine anti-
folates to cells in vitro: potency of methotrexate, and its
a and y substituents,” Biochem. Biophys. Acta,
862:72-80, 1986.
Hoffman and Lasek, “The slow component of axonal trans-
port: Identification of major structural polypeptides of the
axon and their generality among mammalian neurons,” J.
Cell Biol., 66:351-366, 1975.
Holt et al., “Lipofection of cDNAs in the embryonic verte-
brae central nervous system,” Neuron, 4:203-214, 1990.
Horwitz, M.S., “Adenoviridae and their replication,” In: B.
N. Fields and D. M. Knipe (Eds.), Fields Neurology, 2nd
ed., Raven, N.Y., pp. 1679-1721, 1990.
Huanget al., “Introduction of a foreign gene (E. coli lacZ)














mutants: A light and electron microscopic study,” Exp.
Neurol., 115:303-316, 1992.
Imaizumiet al., “Liposome-entrapped superoxide dismutase
ameliorates infarct volume in focal cerebral ischemia,”
Acta Neurochurgia Suppl., 51:236-239, 1990.
Imaizumiet al., “Liposome-entrapped superoxide dismutase
reduces cerebral infarction in cerebral ischemia in rats,”
Stroke, 21:1312-1317, 1990.
Inuzuka et al., “Changes in the concentrations of cerebral
proteins following occlusion of the middle cerebral artery
in rats,” Stroke, 21:917—922, 1990b.
Inuzuka et al., “Suppressive effect of E-64c 0 ischemic
degradation of cerebral proteins following occlusion of
the middle cerebral artery in rats. Brain Res.,
526:177-179, 1990a.
Jenkins et al., “Increased vulnerability of the mildly trau-
matized brain to cerebral ischemia: the use of controlled
secondary ischemia as a research tool to identify common
or different mechanisms contributing to mechanical and
ischemic brain injury,” Brain Res., 477:211-234, 1989.
Jiang et al., “Moderate hypothermia reduces blood-brain
barrier disruption following traumatic brain injury in the
rat,” Acta Neuropathologica, 84:495-500, 1992.
Jiao et al., “Persistence of plasma DNA and expressionin rat
brain cells in vivo,” Exp. Neurol., 115:400-413, 1992.
Johnson, G., “Chemical neurotoxins as denervation tools in
neurobiology,” Ann. Rev. Neurosci., 3:169-187, 1980.
Johnsonet al., “Degradation of microtubule-associated pro-
tein 2 (MAP2) andbrain spectrin by calpain: A compara-
tive study,” J. Neurochem., 56:1630-1638, 1991.
Johnsonetal., “Effects of gene transfer into cultured CNS
neurons with a replication-defective herpes simplex virus
type 1 vector,” Mol. Brain res., 12:95-102, 1992.
Julien and Mushynski, “Multiple phosphorylation sites in
mammalian neurofilament polypeptides,” J. Biol. Chem.,
257:10467-10470, 1982.
Kaech et al., “Expression of E. coli B-galactosidase in
low-density cultures of hippocampal neurons,” Soc. Neu-
rosci. Abstr., 19:1746, 1993.
Kaku et al., “Alterations of a 200 kDa neurofilament in the
rat hippocampus after forebrain ischemia,” J. Cereb.
Blood Flow Metab., 13:402-408, 1993.
Kamakuraet al., “Calctum-activated neutral protease in the
peripheral nerve, which requires “uM order Ca**, and its
effect on the neurofilament triplet, J. Neurosci. Res.,
13:391—403, 1985.
Kawaja et al. “Somatic gene transfer of nerve growth
factors promotes the survival of axotomized septal neu-
rons and the regeneration of their axons in adult rats,” J.
Neurosci., 12:2849-2864, 1992.
Kromer, L. F., “Nerve growth factor treatment after brain
injury prevents neuronal death,” Science, 235:214-216,
1987.
Kudoetal., “Neuropathological changesin the gerbil brain
after chronic hypoperfusion,” Stroke, 24:259-265, 1993.
Kyte & Doolittle. J. Mol. Biol. 157:105-132, 1982.
la Gal la Salle et al., “An adenovirus vector for gene transfer
into neuronsandgliain the brain,” Science, 259:988-990,
1993.
Lee et al., “Inhibition of proteolysis protects hippocampal
neurons from ischemia,” Proc. Natl Acad. Sci. USA,
88:7233-7237, 1991.
Levi-Montalcini and Cohen, “Effects of the extract of the
mouse submaxillary salivary glands on the sympathetic
system of mammals,” Aun. NYAcad. Sci., 85:324-341,
1960.
Li et al., “Gene transfer in primary cultures of human




Lindsay and Rohrer, “Placodal sensory neurons in culture:
Nodose ganglion neurons are unresponsive to NGF, lack
NGFreceptors but are supported by a liver-derived neu-
rotrophic factor,” Dev. Biol., 112:30-48, 1985.
Lindsay, R. M., “Brain-derived neurotrophic factor an NGF-
related neurotrophin. In: Neurotrophic factor Fallon J. A.,
Loughlin, S. E., eds. New York, Academic Press 257-284,
1993.
Lopez-Berestein et al., Liposomal amphotericin B for the
treatment of systemic fungal infections in patients with
cancer: A preliminary study,” J. Infect. Diseases, 151(4)
:704-710, 1985.
Lyckeet al., “Herpes simplex virus infection of the human
sensory neuron: An electron microscopy study,” Arch.
Virol., 101:87-104, 1988.
Lyeth et al., “Prolonged memory impairmentin the absence
of hippocampal cell death following traumatic brain
injury in the rat,” Brain Res., 526:249-258, 1990.
MacGregor and Caskey, “Construction of plasmids that
express E£. coli B-galactosidase in mammalian cells,”
Nucl. Acids Res., 17(6):2365, 1989.
Machidaet al., “NGF induction of the gene encoding the
protease transin accompanies neuronal differentiation in
PC12 cells,” Neuron, 2:1587-1596, 1989.
Maisonpierre et al., “NT-3 BDNF and NGFin the develop-
ing rat nervous system: parallel as well as reciprocal
patterns of expression,” Neuron, 5:501-509, 1990b.
Maniatis et al., Molecular Cloning: A Laboratory Manual,
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
1982.
Meaneyetal., “The significance of impact velocity in the
production of axonal injury in the contralateral cerebral
cortex using rigid indentation,” J. Neurotrauma, 9:393,
1992.
Meilio et al., “Increased production of the trkB protein
tyrosine kinase receptor after brain insults,” Neuron,
10:151-164, 1993.
Mellgren and Murachi, Intracellular Calcium-Dependent
Proteolysis. CRC Press, Inc.: Boca Raton, Fla., 1990.
Montero and Hefti, “Rescue of lesioned septal cholinergic
neurons by nerve growth factor: specificity and require-
ment for chronic treatment,” J. Neurosci., 8:2986-2999,
1988.
Mori and Fukatsu, “Anticonvulsant effect of DN-1417, a
derivative of thyrotropin-releasing hormone, and lipo-
some entrapped DN-1417, on amygdaloid-kindledrats,”
Epilepsia, 33(6):994-1000, 1992.
Morse et al., “Brain-derived neurotrophic factor (BDNF)
prevents the degeneration of medical septal cholinergic
neurons following fimbria transection,’ J. Neurosci.,
13(10):4146-4156, 1993.
Mortimeret al., “Head trauma as a risk factor for Alzhe-
imer’s disease: a collaborative re-analysis of case-control
studies,” Int. J. Epidemiol, 20(supp1 2):528-535, 1991.
Muller et al., “Laboratory methods: Efficient transfection
and expression of heterologous genes in PC12 cells,”
DNA Cell Biol., 9(3) :221-229, 1990.
Nabel et al., “Gene transfer in vivo with DNA-liposome
complexes: safety and acute toxicity in mice,” Human
Gene Ther., 3:267—275, 1992a.
Nabel et al., “Gene transfer in vivo with DNA-liposome
complexes: lack of autoimmunity and gonadal
localizations,” Human Gene Ther., 3:649-656, 1992b.
Nakamuraetal., “Differential distribution of 68 kD and 200
kD neurofilamentproteins in the gerbil hippocampus and
their early distributional changes following transient fore-














Nicolau and Gersonde, “Incorporation of inositol hexaphos-
phate into intact red blood cells,” Naturwissenschaften,
66:563-566, 1979.
Nistico et al., “NGF restores decrease in catalase activity &
increases superoxide dismutase & GSH peroxidaseactiv-
ity in the brain of aged rats,” Fice Rad. -Biol. Mod.,
12:177-181, 1992.
Nixon and Marotta, “Degradation of neurofilament proteins
by purified human brain cathepsin D.,” J. Neurochem.,
43:507-516, 1984.
Nixon and Sihang, “Neurofilament phosphorylation: A new
look at regulation and function,” INS, 14:501-506,
1991.
Oliver et al., “The protease inhibitor leupeptin interferes
with the development of LTP in hippocampal slices,”
Brain Res., 505:233, 238, 1989.
Ono et al., “Plasmid DNAs directly injected into mouse
brain with lipofectin can be incorporated and expressed
by brain cells,” Neuroscience Letters, 117:259-263, 1990.
Palmeret al., “Traumatic brain injury-induced excitotoxicity
assessed in a controlled impact model,” J. Neurochem.,
61:2015-2023, 1993.
Pant, H. C., “Dephosphorylation of neurofilament proteins
enhances their susceptibility to degradation by calpain,”
Biochem. J., 256:665-668, 1988.
Perez-Polo, J. R. (ed.), Handbook of Nervous System
Factors, CRC Press, Inc., Boca Raton, Fla., 1987.
Perlmutteret al., “The ultrastructural localization of calcium
activated protease ‘Calpain’ in rat brain,” Synapse,
2:79-88, 1988.
Phillips et al., “BDNF mRNAis decreased in the hippoc-
ampus of individual with Alzheimer’s disease,” Neuron,
7:695-702, 1991.
Pietrini et al., “Panencephalopathic type of Cruetzfeld-Jacob
disease with neuropathological features similar to Pick’s
disease,” Clin. Neuropathol., 12:1-6, 1993.
Pikul et al., “In vitro killing of melanoma by liposome-
delivered intracellular irradiation,” Arch. Surg.,
122:1417-1420, 1987.
Povlishock, J. T., “Pathobiology of traumatically induced
axonal injury in animals and man,” Amn. Emerg. Med.,
22:980-986, 1993.
Ramet al., “In situ retroviral-mediated gene transfer for the
treatment of brain tumorsin rats,” Cancer Res., 53:83-88,
1993.
Richardson and Ebendal, “Nerve growth activities in rat
peripheral nerve,” Brain Res., 246:57-64, 1982.
Roberts et al., “B/A4 amyloid protein deposition in brain
after head trauma,” Lancet, 338:1422-1423, 1991.
Roessler and Davidson, “Direct plasmid mediated transfec-
tion of adult murine brain cells in vivo using cationic
liposomes,” Neurosci. Lett., 167:5-10, 1994.
Rosenberget al., “Grafting genetically modified cells to the
damaged brain: restorative effects of NGF expression,”
Science, 242:1575-1578, 1988.
Rylett et al., “Acetylcholine synthesis and release following
continuous intracerebral administration of NGF in adult
and aged Fischer-344rats,” J. Neurosci., 13:3956-3963,
1993.
Sambrook, J., et al. (1989), Molecular Cloning: A Labora-
tory Manual, Cold Spring Harbor Laboratory, Cold Spring
Harbor, N.Y.
Sampath et al., “Effects of NGF on glutathione-peroxidase
and catalase, in PC12 cells,” J. Neurochem., (submitted)
1993.
Sautter et al, “GM, ganglioside treatment reduces visual




Schlaepfer and Zimmerman, “An immunoblot study of
neurofilament degradation in situ and during calcium-
activated proteolysis,” J. Neurochem., 644:502-509,
1985a.
Schlaepfer and Zimmerman, “Mechanisms underlying the
neuronal response to ischemic injury. Calcium-activated
proteolysis of neurofilaments,” Prog. Brain Res.,
63:185-196, 1985b.
Schlaepferet al., “Persistence of immunoreactive neurofila-
ment protein breakdownproducts in transected rat sciatic
nerve,” J. Neurochem., 43:857-864, 1984.
Shaw, G., “Neurofilaments: Abundant but mysterious
structures,” Bioessays, 4:161—-166, 1986.
Simanand Noszek,“Excitatory amino acids activate calpain
1 and induce structural protein breakdown in vivo,”
Neuron, 1:279-287, 1988.
Siman et al., “Brain fodrin: Substrate for calpain 1, an
endogenous calcium-activated protease,” Proc. Natl.
Acad. Sci. USA, 81:3572-3576, 1984.
Simmonset al., “A complete protocol for in situ hybridiza-
tion of messenger RNAs in brain and other tissues with
radiolabeled single-stranded RNA probes,” J.
Histotechnol., 12:169-181, 1989.
Sternbergeret al., “Aberrant neurofilament phosphorylation
in Alzheimer’s disease,” Proc. Natl. Acad. Sci. USA,
82:4274-4276, 1985.
Stewart et al., “Gene transfer in vivo with DNA-liposome
complexes: safety and acute toxicity in mice,” Human
Gene Ther., 3:267—275, 1992.
Storm et al., “Potential pitfalls in in vitro antitumoractivity
testing of free and liposome-entrapped doxorubicin,” J.
Pharm. Sci., 77(10):823-830, 1988.
Taft et al., “Hypothermia attenuates the loss of hippocampal
microtubule-associated protein 2 (MAP2) following trau-
matic brain injury,” J. Cereb. Blood Flow Metab.,
13:796-802, 1993.
Taft et al., “Microtubule-associated protein 2 levels decrease
in hippocampus following traumatic brain injury,” J.
Neurotrauma, 9:281-290, 1992.
Teng and Greene, “Depolarization maintains neurites and
priming of PC12 cells after nerve growth factor
withdrawal,” J. Neurosci., 13(7):3124-3135, 1993.
Thompsonet al., “Transient promoter activity in primaryrat
mammary epithelial cells evaluated using particle bom-
bardment gene transfer,” In Vitro Cell Dev. Biol.,
29A:165-170, 1993.
Tomita et al., “Direct in vivo gene introduction into rat
kidney,” Nippon-Rinsho, 50(12):2874-2878, 1992.
Towbin et al., “Electrophoretic transfer of proteins from
polyacrylamide gels to nitrocellulose sheets: Procedure
and some applications,’ Proc. Natl. Acad. Sci. USA,
76:4350-4354, 1979.
Troost et al., “Neurofilament and glial alterations in the
cerebral cortex in ALS,” Acta Neuropathol., 84:664—-673,
1992.
Turner et al., “Expression of p75*°F*® in the olfactory
system following peripheral deafferentation,” Neurorep.
5:1023-1026, 1993.
Ulrich et al., “Cytoskeletal immunohistochemistry of Alzhe-












clonal antibodies,” Pathol. Immunol. Pathol. Res.,
6:273-283, 1987.
Wagner et al., “Influenza virus hemagglutinin HA-2
N-terminal fusogenic peptides augment gene transfer by
transferrin-polylysine DNA complexes: toward a syn-
thetic cirus like gene transfer vehicle,” Proc. Natl. Acad.
Sci. USA, 89:7934-7938, 1992.
Whitson et al., “Controlled cortical impact injury alters
amyloid protein precursor levels in rat hippocampus and
cortex,” J. Neurotrauma Abst., 1994.
Williams and Rylett, “Exogenous nerve growth factor
increases the activity of high-affinity choline uptake and
choline acetyltransferase in brain offisher 344 malerats,”
J. Neurochem., 55:1042-1049, 1990.
Williamset al., “Continuous infusion of nerve growth factor
prevents basal forebrain neuronal death after fimbria-
fornix transfection,” Proc. Natl. Acad. Sci. USA,
83:9231-9235, 1986.
Wilsonet al., “Biological properties of poliovirus encapsu-
lated in lipid vesicles: antibody resistance and infectivity
in virus-resistant cells,” Proc. Natl Acad. Sci. USA,
7A4(8):3471-3475, 1977.
Wilsonet al., “The introduction of poliovirus RNAinto cells
via lipid vesicles (liposomes),” Cell, 17:77-84, 1979.
Wolf et al., “Retrovirus mediated gene transfer of f-nerve
growth factor into mouse pituitary line AtT-20,” Mol.
Biol. Med., 5:43-49, 1988.
Wong and Neumann,“Electric field mediated gene transfer,”
Biochem. Biophys. Res. Commun., 107(2) :584—-587,
1982.
Wuet al., “Receptor-mediated gene delivery in vivo: partial
correction of genetic analbuminemia in Nagaserats,” J.
Biol. Chem., 266:14338-14342, 1991.
Yaghmai and Povlishock, “Traumatically induced reactive
change as visualized through the use of monoclonal
antibodies targeted to neurofilament subunits,” J. Neuro-
pathol. Exp. Neurol., 51:158-176, 1992.
Yamadaet al., “Retrovirus-mediated gene transfer targeted
to malignant gliomacells in murine brain,” Jap. J. Cancer
Res., 83(12):1244-1247, 1992.
Yanget al., “Alterations of protein kinase C in rat hippoc-
ampusfollowing traumatic brain injury,” J. Neurotrauma,
10:287-295, 1993.
Yanget al., “In vivo andin vitro gene transfer to mammalian
somatic cells by particle bombardment,” Proc. Natl. Acad.
Sci. USA, 87:9568-9572, 1990.
Yanget al., “Optimizing liposome-mediated gene transfer in
primary septo-hippocampalcell cultures,” Neurosci. Lett.,
(In Press), 1994.
Yang et al., “Sustained expression of functional nerve
growth factors in primary septo-hippocampalcell cultures
by liposome-mediated gene transfer,” Neurosci. Lett.,
182: this issue, 1994.
Yang et al., “Temporal and regional profile of BDNF and
NGF mRNAexpression after cortical impact injury in rat
brain,” 23nd Annual Meeting Society for Neuroscience,
Washington, D.C., Nov. 1993, J. Neurotrauma Abstracts,
1993.






(iii) NUMBER OF SEQUENCES: 6
(2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
GCAAACATGT CTATGAGGGT 20
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
GGTCAGTGTA CATACACAGG 20
(2) INFORMATION FOR SEQ ID NO:3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
GGCATGCTGG ACCCAAGCTC 20
(2) INFORMATION FOR SEQ ID NO:4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
GCGCTTGCTC CGGTGAGTCC 20
(2) INFORMATION FOR SEQ ID NO:5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)






(2) INFORMATION FOR SEQ ID NO:6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)





1. A method for treating nerve cells by transfection
comprising the steps of:
(a) selecting a nerve cell tissue site of an animal suffering
a traumatic brain or spinal cord injury;
(b) administering to the cells of said nerve tissue site of
said animalby direct injection an effective amountof a
composition comprising a nucleic acid segment encod-
ing a neurotrophin, and a liposome comprising at least
one cationic lipid; wherein said neurotropin is selected
from the group consisting of nerve growth factor
(NGF)and brain-derived nerve growth factor (BDNF),
and wherein said cells of said nerve tissue site in said
animal are transfected with said composition resulting
in the transient expression of said neurotrophin in said
cells causing a reduction of neuron death or cytoskel-
etal protein damage in said nervetissuesite.
2. The method of claim 1, wherein said animalis a human.
3. The method of claim 1, wherein the liposome further
comprises a phospholipid and wherein the cationic lipid is
DOTMAand the phospholipid is DOPE.
4. The method of claim 3, wherein DOTMA and DOPE
are in about a 1:1 ratio.
5. The method of claim 1, wherein the nucleic acid
segment and the liposomeare in a ratio from about 1:1 to
about 1:9.
6. The method of claim 5, wherein the ratio is about 1:3.
7. The method of claim 1, wherein the nucleic acid
segment comprises a promoter.
8. The method of claim 7, wherein the promoter is CMV
or RSV.
9. The method of claim 1, wherein the transient expres-
sion persists for at least a day.
10. The method of claim 1, wherein the transient expres-
sion persists for at least a week.
11. The method of claim 1, wherein the transient expres-
sion persists for at least two weeks.
12. The method of claim 1, wherein the direct injection is
by syringe, an osmotic pump,a ventricular cannuli injection
device or an intraparenchymal injection device.
13. The method of claim 1, wherein the cytoskeletal
protein is a neurofilament protein.
14. The method of claim 13, wherein the neurofilament











15. A method for treating nerve cells by transfection
comprising the steps of:
(a) selecting a nerve cell tissue site of a human suffering
a traumatic brain or spinal cord injury;
(b) administering to the cells of said nerve tissue site of
said human bydirect injection an effective amountof a
composition comprising a nucleic acid segment encod-
ing a neurotrophin, and a liposome comprising at least
one cationic lipid; wherein said neurotropin is selected
from the group consisting of nerve growth factor
(NGF)and brain-derived nerve growth factor (BDNF),
and wherein said cells of said nerve tissue site in said
human are transfected with said composition resulting
in the transient expression of said neurotrophin in said
cells causing a reduction of neuron death or cytoskel-
etal protein damage in said nervetissuesite.
16. The method of claim 15 wherein the liposomefurther
comprises a phospholipid and wherein the cationic lipid is
DOTMAand the phospholipid is DOPE.
17. The method of claim 16, wherein DOTMA and DOPE
are in about a 1:1 ratio.
18. The method of claim 17 wherein the nucleic acid
segment and the liposomeare in a ratio from about 1:1 to
about 1:9.
19. The method of claim 18, wherein the ratio is about 1:3.
20. The method of claim 15, wherein the nucleic acid
segment comprises a promoter.
21. The method of claim 20, wherein the promoter is
CMVor RSV.
22. The method of claim 15, wherein the transient expres-
sion persists for at least a day.
23. The method of claim 15, wherein the transient expres-
sion persists for at least a week.
24. The method of claim 15, wherein the transient expres-
sion persists for at least two weeks.
25. The method of claim 15, wherein the direct injection
is by syringe, an osmotic pump, a ventricular cannuli
injection device or an intraparenchymal injection device.
26. The method of claim 15, wherein the cytoskeletal
protein is a neurofilament protein.
27. The method of claim 26, wherein the neurofilament
protein is a 200 kDa, a 150 kDa,or a 68 kDa neurofilament
protein.
